Всемирная организация здравоохранения (ВОЗ / WHO) · Governing Bodies documents

فريق الخبراء الاستشاريين العامل المعني بتمويل وتنسيق البحث والتطوير

31 декабря 2012 г. Всемирная организация здравоохранения

Полный текст размещён на сайте публикующей организации. lawenc.com индексирует метаданные и ведёт на официальный источник.

Полный текст

‫ج‪٢٤/٦٥‬‬ ‫ﻝ ‪٢٠١٢‬‬ ‫ﺎن‪ /‬أﺑرﻳﻝ‬ ‫‪ ٢٠‬ﻧﻳﺳﺎ‬ ‫‪A‬‬ ‫‪A65/24‬‬ ‫‪4‬‬

‫ﻟﺳﺗون‬ ‫ﻣﺳﺔ واﻟ‬ ‫ﻳﺔ اﻟﺧﺎﻣ‬ ‫اﻟﺻﺣﺔ اﻟﻌﺎﻟﻣﻳ‬ ‫ﺔ‬ ‫ﺟﻣﻌﻳﺔ‬ ‫ﻣن ﺟدوﻝ اﻷﻋﻣﺎﻝ اﻟﻣؤﻗت‬ ‫‪ ١٤-١٣‬ن‬ ‫اﻟﺑﻧد ‪١‬‬

‫ن اﻟﻌﺎﻣﻝ‬ ‫ﺷﺎرﻳﻳن‬ ‫ﻻﺳﺗﺷ‬ ‫اء اﻻ‬ ‫اﻟﺧﺑر‬ ‫ر‬ ‫ﻓرﻳق‬ ‫ر‬ ‫ﻟﺗطوﻳر‬ ‫ث واﻟﺗ‬ ‫ﻧﺳﻳق اﻟﺑﺣث‬ ‫ﺑﺗﻣوﻳﻝ وﺗﻧﺳ‬ ‫ﻌﻧﻲ ﺑ ﻝ‬ ‫اﻟﻣﻌ‬ ‫ﻣﻌﻳ ــﺔ‬ ‫ة اﻟﻌﺎﻣــﺔ ﺑ ــﺄن ﺗﺣﻳــﻝ إﻟــﻰ ﺟﻣ‬ ‫ﻳر‬ ‫رف اﻟﻣ ــدﻳ‬ ‫ﻟﻣﻳ ــﺔ ج ص ع ‪ ،٢٨-٦٣‬ﺗﺗﺷ ــر‬ ‫اﻟﺻ ــﺣﺔ اﻟﻌﺎﻟ‬ ‫ﺟﻣﻌﻳ ــﺔ ﺻ‬ ‫ار ﺟ‬ ‫ﺗﻣﺎﺷ ــﻳﺎً ﻣ ــﻊ ﻗـ ـر‬ ‫ﺑﺣــث‬ ‫وﺗﻧﺳــﻳق اﻟﺑ‬ ‫ﻝ اﻟﻣﻌﻧــﻲ ﺑﺗﻣوﻳــﻝ و‬ ‫رﻳﻳن اﻟﻌﺎﻣــﻝ‬ ‫اء اﻻﺳﺗﺷــﺎر‬ ‫اﻟﺗﻘرﻳــر اﻟﺧﺗــﺎﻣﻲ ﻟﻔرﻳــق‬ ‫اﻟﺳــﺗﻳن ﺗﻘ‬ ‫ﻟﺧﺎﻣﺳــﺔ وا‬ ‫اﻟﻌﺎﻟﻣﻳــﺔ اﻟ‬ ‫اﻟﺻــﺣﺔ ا‬ ‫ق اﻟﺧﺑـر‬ ‫ﺣق‪.‬‬ ‫واﻟﺗطوﻳر اﻟذي ﻳرد ﻓﻲ اﻟﻣﻠﺣ‬

‫ﻌﻧﻲ ﺑﺗﻣوﻳــــﻝ وﺗﻧﺳﻳـق اﻟـﺑـﺣـث واﻟـﺗـطـوﻳـــــــر‬ ‫اء اﻻﺳﺗﺷـﺎرﻳﻳن اﻟــــﻌﺎﻣــــﻝ اﻟﻣــﻌﻧ‬ ‫ﻓـــــرﻳـــق اﻟﺧـﺑـر‬

‫ج‪٢٤/٦٥‬‬

A65/24

ANNEX

.................................................................................. ...................................................

...............................................

A65/24

Annex

.................................................................... ..............................................................

......................................................................... ..................................................... ................................................................. ............................................................ ............................................................ ............................................................ ............................................................................. ................................................................................ ....................... ................................................................................... .................................. ............................. .......... ............................................... .............................................................. ¯ : ¯ ¯ ....................................................................... ................................................

A65/24

Annex

....................

...................................................................... ¯ ..................................................................... ¯ ............................................................. ........................................................................... ........................................................................... .......................................................................... ¯ ......................................................................... ................................................................................ ¯ ¯

.....................................................................................

A65/24

Annex

............................................ ................................................................................. ¯ .......................................................... ............................................................... ............................................................ .......................................... ................................................................... ................................................ ¯ :

.............................................................................

.......................................................... ¯ .................. ............................... ............................. ...... ¯ ¯ ¯ .............................. ¯ : : : ¯

: : ¯

...................................................................................

...................................................................... ......................... ¯ :

A65/24

Annex

................................................................... ......................................... ( ) .............................................................. ................................................. ...................................................... .............................................................

..........................................................................

A65/24

Annex

¯ ¯ ¯

. . . . .

¯ ¯ ¯ ¯ . ¯ ¯ .

. .

¯ . ¯ . ¯

. ¯ .

/ ¯

¯ / . . ¯ .

. .

A65/24

Annex

¯ .

. . −

ٕ .

¯ . ¯ ¯

. . .

. . . ¯

A65/24

Annex

¯ ( )

(

)

. .

A65/24

Annex

A65/24

Annex

) ¯

: ¯ " ¯ " ¯ ¯ ¯ ¯ ¯ ¯

¯ ¯ ٕ

¯ ٕ "

¯ ٕ ¯

A65/24

Annex

: :¯ ¯ () / ( ) ( ) : : / ¯ () ( ) ¯ ( ) () ( ) : ¯ : ¯ ¯ ¯ ¯ ( ) ( ) ( ) ( ) ¯ () ( ) ( ) ( ) ( )

A65/24

Annex

( )

()

( ) ¯ ¯ ¯ () ¯ ( ) ¯ ( ) ( ) ( )

() ( ) ( )

¯ ¯

¯ .

( )

A65/24

Annex

¯ ¯

¯ ¯ :

". ¯ . "

¯ ¯ ¯

¯ ¯ ) (

¯ . . ¯

¯ . ¯ ¯

¯ ¯ " .

http://www.who.int/phi/news/cewg_2011/en/index.html

A65/24

Annex

." ¯ " . . " ¯ .¯ ¯ ."G Finder" . ¯

. ٕ .

¯ ¯ ¯ ¯

¯ . . ¯

. ٕ

¯ ¯ . : . ٕ ¯ .

. ( )

A65/24

Annex

ٕ .

¯ .

) .

(

. :

¯ ٕ

. . ¯

¯ . ¯

¯ . ¯ ¯ " .( ¯

. .

)

A65/24

Annex

. .

. . . ¯ ‚ ¯ ¯ ‚ ‚ . ¯ . ¯

−

. . .

¯ . ‚

. ¯ . ¯

¯ ¯ .

A65/24

Annex

: ¯ : ‚ ‚ . ‚ ‚ ‚ ¯ .

•

. ¯

¯ . . . ¯ . ¯ " ¯ . ¯ ¯ ¯

. ٕ .

¯ .

)¯

A65/24

Annex

¯ .

(

: .

¯ : −

( )

¯ . : ( )

− −

( ) −

.( .

−

) ¯ . ‚ . . ¯ ¯ ‚

‚

¯ G-Finder G-Finder

(

)

. . ¯

¯ ¯

¯ 20

A65/24

Annex

. . . . ¯ ٕ ¯ ¯ ¯ : . . ¯ . • •

. . ( :

(

• • •

A65/24

Annex

•

. . . . ¯

¯ •

• • •

•

. ¯ . •

. ¯

•

. . . .

•

A65/24

Annex

¯ .

•

. •

¯ . ¯ .

•

¯ (" ¯ . ¯ . ¯ ¯ . ") •

•

. . ٕ . ¯

¯ . . ¯

¯ ¯

A65/24

Annex

: ¯ ¯ . . ¯ ¯ . ¯ ¯ ¯ .

. . ..." ¯ ... ¯ ( ). . .

¯ " ٕ ."... . .( ) ¯ " "

. .

( )

(

)

A65/24

Annex

". ...

¯ ¯ ... "

" ٕ

( ) ." / . .( ) . ." ¯ ." ¯ ¯ / / . ": ¯ " / / ¯

( )

¯ : ¯ •

•

A65/24

Annex

•

. ¯ ¯ ¯ ¯ .

•

( ).

¯ "

( ) ".

: : ¯ ¯ " ¯ ( ) ¯ ¯ . ( ) ( ) "

". " " ¯ ¯

A65/24

Annex

( ¯

¯ )

( ( ¯ ) ( ) ¯ )

( . ¯

)

) ("

)

A65/24

Annex

¯ ( ¯ ) ¯

" ( ( ¯ ) )

(

( ¯ .

)

. ¯ ¯

.¯

¯ ¯ ¯ .

.¯

(

¯ ¯ /

) ¯

− −

A65/24

Annex

. ٕ

−

( .

)

. .( ¯ ( .(

( ) .

) )

)

( ٕ ( .( ¯

) ) )

. . " ¯ . " .( . ¯ .( ) ¯ ¯ ¯ . ) ¯ ¯ ¯ ¯ .

.( )

A65/24

Annex

. ¯ (

( (

) ) . ) .

(

)

. ¯ .

¯ .

Intellectual property rights, innovation and public health. Report by the Secretariat. Fifty-sixth World Health Assembly, Geneva, 19−28 May 2003, Document A56/17 (http://apps.who.int/ gb/archive/pdf_files/WHA56/ea5617.pdf, accessed 5 March 2012). Intellectual property rights, innovation and public health. Fifty-sixth World Health Assembly, Geneva, 19−28 May 2003, Resolution WHA56.27 (http://apps.who.int/gb/archive/pdf_files/ WHA56/ea56r27.pdf, accessed 5 March 2012). Public health, innovation and intellectual property rights. Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva, World Health Organization, 2006 (http://www.who.int/intellectualproperty/report/en/index.html, accessed 5 March 2012). Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action. Fifty-ninth World Health Assembly, 22-27 May 2006, Resolution WHA59.24. In document WHA59/2006/REC/1 (Resolutions, decisions and annexes) (http://apps.who.int/phi/Res59_R24-en.pdf, accessed 5 March 2012).

A65/24

Annex

Global strategy and plan of action on public health, innovation and intellectual property. Sixty-first World Health Assembly, 19−24 May 2008, Resolution WHA61.21. In document WHA61/2008/REC/1 (Resolutions, decisions and annexes) (https://apps.who.int/gb/ebwha/ pdf_files/A61/A61_R21-en.pdf , accessed 5 March 2012). Public health, innovation and intellectual property. Report of the Expert Working Group on Research and Development Financing. (Executive Summary). 126th session of the WHO Executive Board, 18−23 January 2010, Document EB126/6 Add.1 (http://apps.who.int/gb/e bwha/pdf_files/EB126/B126_6Add1-en.pdf , accessed 5 March 2012). Research and Development. Coordination and Financing, Report of the Expert Working Group. Geneva, World Health Organization, 2010 (http://www.who.int/phi/documents/ewg_report/ en/index.html , accessed 5 March 2012). Public health, innovation and intellectual property: global strategy and plan of action. Outcome of the consultation on the report of the Expert Working Group on Research and Development: Coordination and Financing. Sixty-third World Health Assembly, 17−21 May 2010, Document A63/6 Add.2 (http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_6Add2-en.pdf, accessed 5 March 2012). Establishment of a consultative expert working group on research and development: financing and coordination. Sixty-third World Health Assembly, 17−21 May 2010, Resolution WHA63.28. In document WHA63/2010/REC/1 (Resolutions, decisions and annexes) (http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf, accessed 5 March 2012). WHO Executive Board, 128th session, Geneva, 17–24 January 2011. Summary records. Document EB128/2011/REC/2. Geneva World Health Organization, 2011 (http://apps.who.int/ gb/ebwha/pdf_files/EB128-REC2/B128_REC2-en.pdf, accessed 5 March 2012).

10.

A65/24

Annex

: .

¯ . "

( ) ". ¯ .¯ . ¯ ¯ . ¯ .

¯ . . . ¯

¯ .

.( ) ¯

.( ) ( ) ( ) ( ) : "

A65/24

Annex

( ) ". .

...

. . : . ٕ ¯ ¯ : "

. "... ¯

¯ ¯ . ¯ . ¯ (

( ) ".

¯ ¯ ¯ . : .

.¯ ¯ ¯ )

" .

( ) ". ¯ . 33

A65/24

Annex

. .

. . . ¯ " " ¯ ¯

¯ "

¯ ": ¯

( ) ".

¯ : .

¯ ". ¯

¯ " "

¯ . ¯

( )".

. :

.( )

http://unitingtocombatntds.org/downloads/ press/ntd_event_disease_summaries.pdf.

.http://www.tballiance.org/why/inadequate-treatment.php : ¯ .http://www.dndi.org/press-releases/928-paediatric-hiv.html : .http://www2.ohchr.org/english/law/cescr.htm : ¯ ¯

A65/24

Annex

¯ . (" " . "¯ "

" "

)

" ." " ." – (PhRMA) "¯ ¯ " " .

–"

. . PhRMA

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu : .http://www.pmprb-cepmb.gc.ca/english/View.asp?x=91:

.http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu :

.tp://www.phrma.org/sites/default/files/159/phrma_profile_2011_final.pdf PhRMA

2011 Profile by PhRMA

A65/24

Annex

(

) (PhRMA

)

(PhRMA) . .( .( .

) ) . ¯ ¯ .(

( )

) .¯

2011 Profile by PhRMA http://www.phrma.org/sites/default/files/159/phrma_profile_2011_final.pdf

A65/24

Annex

.( . " PhRMA

)

" .

. " "¯ PhRMA

" .

¯ .

. . , .

. .( ¯ ¯ . ¯ ¯ ¯ ¯ " "¯ " " . . ¯ ¯ ¯

–

) ¯ .

IMS Health

) ¯ . ¯ . ¯

( ) ."

)

Global Pharmaceutical Market Outlook: 2015, Express Pharma, http://www.expresspharmaonline.com/ : 20120115/market02.shtml.

A65/24

Annex

) . .( ." ) "

. " " " .( "

) . " " " " ¯

(

" ( . "

¯ " " "

) " . " :

. ¯ ( . ¯ .( ¯ .( . . ¯ ¯ . . . )

. )

)

Chesbrough H. Pharmaceutical innovation hits the wall: how open innovation can help. : Forbes, 25 April 2011http://www.forbes.com/sites/henrychesbrough/2011/04/25/pharmaceuticalinnovation-hits-the-wall-how-open-innovation-can-help

.https://openinnovation.lilly.com/dd/docs/oidd_executive_summary.pdf .http://www.imi.europa.eu/content/history

: :

A65/24

Annex

." "

" . .

.( .( ".

) ) "¯ .

( ) :

(IAVI) (IPM) .(SAAVI)

(EMVI) (MVI) (MMV)

(Aeras) :

http://opendefinition.org

A65/24

Annex

(FIND) (TB Alliance) " (DNDi) Institute for OneWorld Health

. : – ." . . ¯ ٕ . ¯ . "

•

• • • •

– . ) ‚

‚ .¯ .( .( ¯

)

A65/24

Annex

‚ ‚ ¯ ¯ ( ¯

. ‚ .( . ¯

, . . ‚ ‚ ) . " / " ... ¯ .( ¯ " )

‚

) ¯ .

. ( .( ) ( ) ...

. (

¯ ‚ .

)

"G-Finder" (

"G-Finder" . . ‚ .¯

(

( :

G-"

‚ .

"G-Finder" . ¯

‚

) ) "Finder ( .

http://www.policycures.org/projects.html :

A65/24

Annex

‚

. .( )

( ( ) , , , , , , , , , , , , , (

) )

–

"G-Finder"

."G-Finder"

. :

Implicit Price Deflator US Bureau of Economic Analysis http://www.bea.gov/national/index.htm.

A65/24

Annex

. . .( )

(

)

¯ ( ) , , , , , , , , , , , , , , , , , , , , , , , , , , (

)

( "G-Finder" :

"G-Finder" ) .

A65/24

Annex

( ( ) , , , , , , , , , , , , , , , , , (

) )

(

)

"G-Finder" :

. "G-Finder" "G-Finder" 44

.( ) . )

A65/24

Annex

. .

.( )

One World Health Xpert MTB/RIF

/ ( ( /

(

) )

ASAQ

ASMQ NECT

)

–

MenAfriVac JE

A65/24

Annex

ٕ .( . : ¯ ( .

)

"RTS,S" )

−

(

) ( .( ) ) ) ) (

− −

−

( ) .( )

−

BIO Ventures for Global Health

)(

ٕ " . . ¯ ." ¯ . ¯ . 46

A65/24

Annex

¯ ¯ ¯ ( .( . / . ) / .( .

)( )

)

¯ ¯ .(

. .( ‚

) . : ¯

¯ −

) ¯ ¯ ¯

(

−

. −

Medicines Patent

Pool

A65/24

Annex

¯ "

.( ) ¯

. ¯ .( . ¯ ٕ ) . . . . .( ¯ – . ¯ ¯ ¯

‚ .

.( )

. ¯

)

.( )

A65/24

Annex

¯ . . .

¯ –

. ¯

.( ) .( . ¯ . . ¯ . .

) )

(

.http://robinhoodtax.org/latest/1000-economists-tell-g20-support-robin-hood-tax

http://www.leadinggroup.org : http://robinhoodtax.org :

A65/24

Annex

)

(

. .

. ¯ .

. ٕ . . ٕ . . . . ) ‚ . . .Gates W. Innovation with impact: financing 21st century development : . . ¯ ¯ ¯ . . ¯ ¯

(

A65/24

Annex

)(

. ) / ( ) ¯

: . "

. . .

. .

( ) ". .

¯ . : ( ) − − − − −

.( :

)

−

− −

/ ( )

− −

.http://www.un.org/esa/ffd/overview :

A65/24

Annex

− −

. . : ¯

−

. . ". ...

" . ¯

: "

( ) ". : ¯ ¯ ".

¯ ¯

..."

" ¯

( ) ". : ”G-Finder" ..." ¯ ...

A65/24

Annex

( ) ". –¯ ¯

ٕ . . ¯

¯ .

Global strategy and plan of action on public health, innovation and intellectual property. Sixty-first World Health Assembly, 19−24 May 2008, Resolution WHA61.21. In document WHA61/2008/REC/1 (Resolutions, decisions and annexes) (http://apps.who.int/gb/ ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf, accessed 5 March 2012). Projan S. Why is big pharma getting out of antibacterial drug discovery? Current Opinion in Microbiology, 2003, 6:427–430. Mossiailos E et al. Policies and incentives for promoting innovation in antibiotic research. Copenhagen, World Health Organization/European Observatory on Health Systems and Policies, 2010 (http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf, accessed 1 March 2012). Kesselheim A, Outtersson K. Improving antibiotic markets for long-term sustainability. Yale Journal of Health Policy, Law & Ethics, Winter 2011, Vol. 11 (http://papers.ssrn.com/ sol3/papers.cfm?abstract_id=1716942, accessed 1 March 2012). Priya S, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options. London, Office of Health Economics, 2011 (http://www.ohe.org/publications/article/new-drugs-to-tackle-antimicrobial-resistance5.cfm, accessed 1 March 2012). Outterson K, Pogge T, Hollis A. Combating antibiotic resistance through the Health Impact Fund. Law and Economics Research Paper No. 11-30. Boston, MA, Boston University School of Law, 2011 (http://ssrn.com/abstract=1866768 or http://dx.doi.org/10.2139/ssrn.1866768, accessed 1 March 2012). Public health, innovation and intellectual property rights. Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva, World Health

2. 3.

A65/24

Annex

Organization, 2006 (http://www.who.int/intellectualproperty/report/en/index.html, accessed 1 March 2012). 8. 9. Constitution of the World Health Organization. In: Basic Documents, 45th ed. Geneva, World Health Organization, 2005. Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. A/HRC/7/11, UN Human Rights Council, 31 January 2008 (http://daccess-ddsny.un.org/doc/UNDOC/GEN/G08/105/03/PDF/G0810503.pdf? OpenElement, accessed 1 March 2012). Cockburn IM. Is the pharmaceutical industry in a productivity crisis? In: Lerner J, Stern S, eds: Innovation policy and the economy, Vol 7. Cambridge, MA, MIT Press, 2007 (http://www.nber.org/chapters/c0032.pdf, accessed 5 March 2012). Jeff Hewitt et al. Beyond the shadow of a drought: the need for a new mindset in Pharma R&D 2011, Health and Life Sciences, Oliver Wyman, 2011 (http://www.oliverwyman.com/4638.htm, accessed 5 March 2012). Pharmaceutical pricing policies in the global market. Paris, Organization for Economic Co-operation and Development, 2008 (http://www.oecd.org/dataoecd/36/2/41303903.pdf, accessed 5 March 2012). New drug development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. United States Government Accountability Office, GAO-07-49, November 2006 (http://www.gao.gov/assets/260/253726.pdf, accessed 1 March 2012). Morgan S. et al. eds. Breakthrough drugs and growth in expenditure on prescription drugs in Canada. British Medical Journal, 2005, 331:815-816. LaMattina J. The impact of mergers on pharmaceutical R&D. Nature Reviews, Drug Discovery, August 2011, 10: 559-560 (http://www.nature.com/nrd/journal/v10/n8/pdf/nrd3514.pdf, accessed 1 March 2012). Tempest B. The Structural Changes in the Global Pharmaceutical Marketplace and Their Possible Implications for Intellectual Property, UNCTAD/ICTSD Policy Brief No. 10 July 2011 (http://ictsd.org/downloads/2011/12/the-structural-changes-in-the-globalpharmaceutical-marketplace-and-their-possible-implications-for-intellectualproperty.pdf, accessed 1 March 2012). Witty A. New strategies for innovation in global health: a pharmaceutical industry perspective. Health Affairs, 2011, 30(1): 118−126 (http://globalhealthprogress.org/mediacenter/wp-content/uploads/A-Witty-HealthAffairs.pdf, accessed 1 March 2012). Chesbrough H. Pharmaceutical innovation hits the wall: how open innovation can help. Forbes, 25 April 2011 (http://www.forbes.com/sites/henrychesbrough/2011/04/25/pharmaceutical-innovationhits-the-wall-how-open-innovation-can-help, accessed 1 March 2012).

10.

11.

12.

13.

14. 15.

16.

17.

18.

A65/24

Annex

19.

Allarakhia M. Open innovation case study: Pfizer’s centers for therapeutic innovation. April 2011 (http://www.bioendeavor.net/newsUrl.asp?nId=294659, accessed 1 March 2012). Munoz B. Can Open-Source Drug R&D Repower Pharmaceutical Innovation? Clinical Pharmacology and Therapeutics, 87:5, 2010 (http://emoglen.law.columbia.edu/twiki/pub/ LawNetSoc/BahradSokhansanjFirstPaper/87ClinPharmTher534_open_source_drug_di sc_Munos_2010.pdf, accessed 1 March 2012). Grams C. Open innovation and open source innovation: what do they share and where do they differ? Open Source.com, 2010 (http://opensource.com/business/10/10/openinnovation-and-open-source-innovation-what-do-they-share-and-where-do-they-diffe, accessed 1 March 2012). Hunter J. Challenges for pharmaceutical industry: new partnerships for sustainable human health, Philosophical Transactions of the Royal Society A, 369(1942):18171825, 2011 (http://rsta.royalsocietypublishing.org/content/369/1942/1817.full.pdf+html, accessed on 1 March 2012). The Commission on Health Research for Development, Health Research: Essential Link to Equity in Development, Oxford University Press, 1990 (http://www.hsph.harvard.edu/healthresearch/files/essentiallinktoequityindevelopment.pdf, accessed 1 March). Ad Hoc Committee on Health Research Relating to Future Intervention Options, Investing in health research and development, Geneva, 1996 (Document TDR/Gen/96.1) (http://apps.libdoc.who.int/hq/1996/TDR_Gen_96.1_pp1-34.pdf, accessed 1 March 2012). Mary Anne Burke and Stephen A Matlin (eds.), Global Forum for Health Research, Monitoring Financial Flows for Health Research 2008, Geneva, 2008 (http://announcementsfiles.cohred.org/gfhr_pub/assoc/s14888e/s14888e.pdf, accessed 1 March 2012). Moran M et al. G-Finder Report 2011: Neglected Disease Research and Development: Is Innovation under Threat? Policy Cures, London, United Kingdom, 2011 (http://www.policycures.org/downloads/g-finder_2011.pdf, accessed on 12 December 2011). Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. Drug development for neglected diseases: deficient market and a public-health policy failure. Lancet 22; 359(9324): 2188–94, 2002 (http://msf.openrepository.com/msf/bitstream/10144/28441/1/Access%20Trouiller% 202002.pdf, accessed on 1 March 2012). Cohen J Dibner, MS Wilson A Development of and Access to Products for Neglected Diseases. PLoS ONE 5(5): May 2010 (http://www.plosone.org/article/info:doi%2F10.1371% 2Fjournal.pone.0010610, accessed 1 March 2012).

20.

21.

22.

23.

24.

25.

26.

27.

28.

A65/24

Annex

29. 30. 31.

Burness Communications The Need for Global Health R&D and Product Development Partnerships: Message Manual November 2011 Unpublished. BVGH Global Health Primer Database (www.globalhealthprimer.org, accessed 27 January 2012). Waning B., Diedrichsen E., Moon S., A lifetime to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. Journal of the International AIDS Society 2010, 13: (35) (http://www.jiasociety.org/content/13/1/35 , accessed September 2011). Holmes CB, Coggin W, Jamieson D, Mihm H, Granich R, Savio P, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA. 2010;304(3):313-20. Medecins Sans Frontieres, Untangling the Web of Antiretroviral Price Reductions 14th Edition, 2011 (http://apps.who.int/medicinedocs/documents/s18716en/s18716en.pdf, accessed 13 March 2012). UNAIDS Data Tables 2011 (http://www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2011/JC2225_UNAIDS_datatables_en.pdf, accessed 1 March 2012). Resolution WHA 58.4. In: Fifty-eighth World Health Assembly, Geneva, 25 May 2005. Geneva, World Health Organization, 2005 (http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_34-en.pdf, accessed 1 March 2011). Murray C et al Global malaria mortality between 1980 and 2010: a systematic analysis. The Lancet, Volume 379, Issue 9814, Pages 413 - 431, 2012 (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60034-8/fulltext, accessed 1 March 2012). Financing Global Health 2011: Continued Growth as MDG Deadline Approaches. Institute for Health Metrics and Evaluation, 2011 (http://www.healthmetricsandevaluation.org/ publications/policy-report/financing-global-health-2011-continued-growth-mdgdeadline-approaches, accessed 1 March 2012). Tobin J. A Proposal for International Monetary Reform Cowles Foundation, Discussion Paper No. 5061978 (http://dido.econ.yale.edu/P/cd/d05a/d0506.pdf, accessed 1 March 2012). Barker A. Transaction tax proposal knocks shares, Financial Times, 17 August 2011 (http://www.ft.com/cms/s/0/0681a2c2-c8a4-11e0-a2c800144feabdc0.html#axzz1cj35jSHE, accessed 1 March 2012). European Commission, Proposal for a Council Directive on a common system of financial transaction tax and amending Directive 2008/7/EC, Brussels, 2011 (http://ec.europa.eu/taxation_customs/resources/documents/taxation/other_taxes/finan cial_sector/com(2011)594_en.pdf, accessed 1 March 2012).

32.

33.

34.

35.

36.

37.

38.

39.

40.

A65/24

Annex

41.

The solidarity tobacco contribution. A new international health‐financing concept prepared. Discussion Paper, Geneva, World health Organization, 2011 (http://www.who.int/nmh/events/ un_ncd_summit2011/ncds_stc.pdf, accessed 1 March 2011). Innovation with Impact: Financing 21st Century Development. Report by Bill Gates to G20 leaders, Cannes Summit, 2011 (http://www.thegatesnotes.com/Topics/Development/G20-Report-Innovation-withImpact, accessed 1 March 2012). Cannes G20 Summit Final Declaration, 2011 (http://www.g20-g8.com/g8g20/g20/english/for-the-press/news-releases/cannes-summit-finaldeclaration.1557.html, accessed 12 March 2012). Public health, innovation and intellectual property rights. Geneva, Commission on Intellectual Property Rights, Innovation and Public Health, 2006 (http://www.who.int/ intellectualproperty/report/en/index.html, accessed on 8 October 2011).

42.

43.

44.

: . . ¯

‫متبع‬ ُ ‫معايير التقييم وا سلوب ال‬ .( . . " " ) .

. . .¯ -

‫ معايير فريق الخبراء ا ستشاريين العامل‬١-٣ ‫الجدول‬ ¯ – .

A65/24

Annex

¯ . ¯ / /

ٕ . ) ) ( .( . . ¯ ¯

. .

. / . .

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫ا ليات الخاضعة للتقييم‬ ‫¯‬ ‫(‬ ‫)‬ ‫¯‬ ‫‪.‬‬ ‫‪.‬‬ ‫‪.‬‬ ‫¯‬

‫‪.‬‬

‫الجدول ‪ ٢-٣‬اقتراحات فريق الخبراء العامل المجمعة ا ثنان والعشرون ومساھمات فريق الخبراء‬ ‫ا ستشاريين العامل‬ ‫¯‬

‫‪.‬‬

‫‬ ‫‬

‫‪.‬‬ ‫‬ ‫¯‬

‫‪.‬‬

‫¯‬ ‫‪.‬‬ ‫‪.‬‬ ‫¯‬ ‫)‬ ‫¯‬ ‫(‬

‫‪.‬‬

‫¯‬

‫¯‬ ‫"(‪.‬‬ ‫‪.‬‬ ‫‪.‬‬ ‫)"‬ ‫¯‬

‫‪59‬‬

A65/24

Annex

. .

. ٕ . . . ( .

)

¯ . ٕ .

. ( . . ¯ . .Franciosi E . ) Maito M

. .

(

)

A65/24

Annex

. .

. . ¯ . . . . . .

. . . . . .

.(" .

") .(BVGH)

¯ ¯

. .Franciosi E .

¯ Maito M

( . . .

)

¯ .

. ¯

Charité Universitätsmedizin

.BUKO Pharma-Kampagne . / . Universität Oldenburg .

Berlin

¯ .

.(ANDI ) ¯

–

A65/24

Annex

. . .Paez P. . .Agarwal . . . .

.Kazi GN.

.Health Insight Ltd

. Agarwal

.Luchini S Leoni P . .Sandroni A Leoni P

)

(

. ¯ . . ¯ .

¯ ) ¯

)

¯ ¯

¯ .( . (

(

)

" " (‫)الشبكة ا فريقية ل بتكار المتعلق بالعقاقير والتشخيص‬ ¯ ( ) . ) " . ( ‫كمثال‬ "

‫ل يدز والعدوى بفيروسه‬ ¯ . . .

A65/24

Annex

. .

¯ ¯

¯ . . .

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫‪.‬‬

‫‪:‬‬

‫‪.‬‬ ‫(‬ ‫ٕ‬ ‫)‬ ‫‪.‬‬ ‫¯‬

‫‪.‬‬

‫ا طار العالمي للبحث والتطوير‬ ‫استناداً إلى مساھمتين وردتانا تقترحان وضع معاھدة وإطار عالمي‪ ،‬رأينا أن الوقت قد حان للنظر في وضع‬ ‫إطار دولي متجانس ومتكامل أو اتفاقية برعاية من منظمة الصحة العالمية بغية دعم أعمال البحث والتطوير‬ ‫ذات ا ولوية في المجال الطبي والمخصصة لع ج ا مراض المنتشرة في البلدان النامية‪.‬‬ ‫وعلى الرغم من أن ا قتراحين يبدوان طموحين‪ ،‬فھما يستحقان تمحصا ً إضافياً‪ .‬ويتضمن ا قتراحان أغراضا ً‬ ‫وأھدافا ً محددة بوضوح‪ ،‬تشمل وضع ھيكل شفاف وتشاركي وفعال لتصريف الشؤون يلبي حاجات تقييم الثغرات‬ ‫في مجالي البحث والتطوير‪ ،‬وتحديد ا ولويات‪ ،‬وتخصيص ا موال ال زمة لتعزيز جھود البحث والتطوير‬ ‫الم ئمة للظروف القائمة في البلدان النامية‪ ،‬وجمع ا موال على المستوى العالمي من مساھمات من الدول‬ ‫ا عضاء وغيرھا من مصادر التمويل المخصصة‪.‬‬ ‫‪.‬‬ ‫‪.‬‬ ‫ٕ‬ ‫‬ ‫‪.‬‬ ‫‬ ‫¯‬

‫¯‬ ‫¯‬

‫‪.‬‬ ‫‬

‫‪:‬‬ ‫‪.‬‬

‫(‪.‬‬

‫‪/‬‬

‫¯‬

‫)‬ ‫ٕ‬

‫‬ ‫‪http://www.who.int/phi/news/cewg_call_for_proposals.pdf‬‬

‫"‬

‫‪64‬‬

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫‪.‬‬

‫¯‬

‫‪.‬‬ ‫‪.‬‬ ‫¯‬ ‫‪.‬‬

‫‪:‬‬

‫‪.‬‬ ‫‪.‬‬

‫¯‬ ‫‪.‬‬

‫‬ ‫¯‬

‫إزالة حصرية البيانات‬ ‫‬ ‫‬ ‫‬ ‫¯‬ ‫‪ٕ .‬‬ ‫‪.‬‬ ‫¯‬ ‫‪ٕ .‬‬ ‫‪.‬‬ ‫¯‬ ‫‬ ‫‪.‬‬ ‫‪.‬‬ ‫‪.‬‬ ‫‬

‫المنح المباشرة للشركات‬ ‫‪.‬‬ ‫¯‬ ‫‪.‬‬ ‫‪.‬‬ ‫‪65‬‬

‫¯ ٕ‬ ‫‪.‬‬

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫‪.‬‬

‫¯‬ ‫‪.‬‬ ‫¯‬ ‫¯‬

‫‪.‬‬

‫¯‬

‫‪.‬‬

‫)‬ ‫¯‬ ‫‪.‬‬

‫‪.‬‬

‫¯‬

‫(‪.‬‬ ‫¯‬ ‫‬ ‫‪.‬‬

‫‪.‬‬

‫الملكية الفكرية الخضراء‬ ‫‪.‬‬ ‫‬ ‫¯‬ ‫¯‬ ‫‬ ‫‪.‬‬ ‫‬ ‫‬ ‫‬ ‫‪.‬‬ ‫‬ ‫‬ ‫¯‬ ‫‪.‬‬ ‫¯‬ ‫‪.‬‬ ‫‪.‬‬ ‫‬ ‫¯‬ ‫‪.‬‬ ‫"‬ ‫"‬ ‫‪.‬‬ ‫¯‬ ‫¯‬

‫(‬

‫)‬

‫‬

‫صندوق ا ثر الصحي‬ ‫¯‬ ‫‪.‬‬ ‫‪.‬‬ ‫‪.‬‬ ‫‪.‬‬

‫‬

‫‪.‬‬

‫¯‬

‫‪66‬‬

A65/24

Annex

. . ¯ ¯ .

¯ .

. .( ¯ . . . ¯ "

" . .

. ¯

)

. " " "

. .

. " " ¯

¯ . .

A65/24

Annex

) .

¯ ¯ .(

" . ¯

" ¯ .

: ¯

. ٕ . ) ¯ .( ¯ ) . .¯ . . . . ( ¯ ) ¯ ¯

. (

A65/24

Annex

. . . ٕ .

. . . ¯ . ¯ .

. ¯ .

¯ .

. . . ( )

Innocentive

¯ ¯ . .

. .

A65/24

Annex

. ¯

. .

. ¯

¯ .

¯ . ¯ ¯ ¯

GlaxoSmithKline

. ) . . . .

¯ (

. . . ¯

. . .

A65/24

Annex

. . .

. . . .

. . . . .

¯ ٕ

. . . .

¯ . ¯ ¯ . . ¯ 71

¯ . ¯

A65/24

Annex

. . ¯ . ¯ .

¯ ¯ . . . . . ¯

¯ ¯ . ¯ ( . ¯

)

A65/24

Annex

. : .

. . . ¯ . ¯ .

A65/24

Annex

¯ ¯ .

¯ ¯ .¯ ¯ . ¯ . . . . . . ¯ ¯ . "

: ."

: . (RED)

•

¯ . . ¯ . . ¯ .

A65/24

Annex

. . ¯

¯ ¯ ¯ . . ¯ ¯

. .

. . . .¯

. . . ¯ . ."Finder-G" .

¯ ¯

: http://www.oecd.org/document/35/0,3746,en_2649_34447_47515235_1_1_1_1,00.html

A65/24

Annex

¯ . ¯ ¯ . ¯ .

¯ ." "

¯ ¯ . ¯

¯ .

( ). ( ) ¯

¯ .

. ¯ ." ¯ ¯ .¯

.MASSIVEGOOD ¯ ¯ . : ¯ . . . ¯ . .

MASSIVEGOOD

. ¯

. .( ) ¯ ¯ ¯

• • •

A65/24

Annex

. . . ¯ ¯ •

• • •

: ¯ ¯

¯ .

Product RED

•

. . . (

¯ ) ¯ . . , , . .( ) . , , . . • •

‚

¯ . /

" /

" http://www.joinred.com/red/#impact

.http://www.biglotteryfund.org.uk/pub_corp_plan11-12.pdf

A65/24

Annex

. "

. " " " .

: "

¯ -

" " " ¯ ." , , " , " ¯

" ¯

¯ "

." " . ¯ ¯

" ¯ .( )

¯ . .

¯ .

. .( ) . ¯

http://www.govtrack.us/congress/billtext.xpd?bill=h110-3678

A65/24

Annex

.( ) .¯ . ¯ . . ¯ ¯

. ٕ

. .

wealth of nations

Adam Smith

.( ) . .( )

http://www.un.org/disarmament/convarms/ArmsTradeTreaty

A65/24

Annex

)

" .(

)

" " ¯

. .( . )

( )

)

ٕ ٕ ¯ . .

)

( ) ¯ ." "

¯ "

. " .( ( ): .(

)

) ) ( )

, ¯ ¯ .

http://www.saprp.org/KnowledgeAssets/knowledge_results.cfm?KAID=4

A65/24

Annex

)

. , ¯ •

: .(

)

•

.( .(

) •

) , . .(

•

) , •

.( .(

) )

. . . . ( . ) ¯ .(

)

http://www.agenziafarmaco.gov.it/en/content/independent-research-drugs

A65/24

Annex

. ) .( )

. ¯ ¯

¯ . .

. .

. ٕ . .

. ¯ / .

¯ " ¯ "

: . ¯

. ¯

http://www.brookings.edu/~/media/Files/Projects/globalhealth/healthsnapshots/airline.pdf

) .

. ,

¯ . . ¯

A65/24

Annex

. ٕ ٕ ."

¯ ¯ ٕ . ¯

¯ .(

" .(

( ) ."

) ¯

)

.( :

)

. ¯ . . . ¯

( ) ." ¯ ¯ . .

A65/24

Annex

" ¯

¯ . " ¯ "

( ) ." " ¯

. ."

" " . ,

(

, . , ,

)

) , , , ,

(

. .

. . .

, ,

, , ,

, ,

. ¯

(

A65/24

Annex

)

: .

.( . . ٕ ¯

ٕ .

: . ¯ . .

: ¯ ¯ . .

(

)

A65/24

Annex

. . . " . ) ¯ ¯ G-Finder"

( ¯ .( .

)

( ) ٤ ٣ ٢ ¯

٦ ¯

١ ¯ )

¯ ( / )( , , , , ,

) ( , , , , ,

) ( / )( , , , , ,

)

) ( ‡ , ,

) ( , , , , , , , , , , , ,

)( ( , , , , , , , , , , , , ,

† , † , ‡ -, , , , , , , ,

-, , , , , ,

, , , , , , , , , , , , ,

A65/24

Annex

٦ ¯

٢ ¯

١ ¯ )

¯ ( / )( , , , , , , , , , , , , , , , , ,

) (

) ( / )( , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

)

) ( ‡ , ‡ , ,

) ( , , , , , , , , , , , , , , , , , , , , , , , , ,

)( ( , , , , , , , , , , , , , , , , , , , , , , , , ,

† , ,

† , ‡ , † , † , ,

‡ , † , † , ‡ , † , ‡ , ,

-, , ,

, , , , , , ,

-, ,

† , -, , ,

-, , ,

, , , , , , ,

‡ † .

A65/24

Annex

(1)

OECD. Gross domestic expenditure on R&D, 1999 and 2009 (GERD). http://www.oecdilibrary.org/sites/sti_scoreboard-2011en/02/05/index.html?contentType=/ns/Chapter,/ns/StatisticalPublication&itemId=/content/chapt er/sti_scoreboard-2011-16en&containerItemId=/content/serial/20725345&accessItemIds=&mimeType=text/html OECD. R&D expenditure by performing sectors, 2009 (GRD). http://www.oecdilibrary.org/sites/sti_scoreboard-2011en/02/05/index.html?contentType=/ns/Chapter,/ns/StatisticalPublication&itemId=/content/chapt er/sti_scoreboard-2011-16en&containerItemId=/content/serial/20725345&accessItemIds=&mimeType=text/html OECD. Public funding of health-related R&D, 2010 (GHRD). (For those marked with †, Health R&D in government budget appropriations or outlays for R&D, 2010.) http://www.oecdilibrary.org/sites/sti_scoreboard-2011en/04/02/index.html?contentType=/ns/Chapter,/ns/StatisticalPublication&itemId=/content/chapt er/sti_scoreboard-2011-35en&containerItemId=/content/serial/20725345&accessItemIds=&mimeType=text/html For those marked with ‡, Gross domestic expenditure on R-D by sector of performance and socioeconomic objective http://www.oecd-ilibrary.org/science-and-technology/data/oecd-sciencetechnology-and-r-d-statistics/gross-domestic-expenditure-on-r-d-by-sector-of-performance-andsocio-economic-objective_data-00188-en GDP in US dollars at current prices and current PPPs http://www.oecd-ilibrary.org/economics/gross-domestic-product-in-us-dollars_2074384x-table3 . See also footnote 9 below. No source – calculation of Government Health R&D divided by Government and Higher Education R&D OECD. Public and private expenditure on health. http://www.oecd-ilibrary.org/sites/factbook2011en/12/03/03/index.html?contentType=/ns/StatisticalPublication,/ns/Chapter&itemId=/content/ch apter/factbook-2011-112en&containerItemId=/content/serial/18147364&accessItemIds=&mimeType=text/html No source – calculation of Government Health R&D divided by Government Health Expenditures

(2)

(3)

(4) (5)

(6)

¯ .(

)

‫منظمة التعاون والتنمي ة ف ي المي دان ا قتص ادي‬ . . ,

A65/24

Annex

. ¯

. ¯ , ¯ ¯

, )

. ¯ G-Finder

. ) . . ( . ¯ .

¯ .

ٕ "

¯ ( )."

/ . †

http://www.easac.eu/fileadmin/PDF_s/reports_statements/The.pdf

. ¯

( (

) . )

) .(

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫¯‬ ‫¯‬

‫¯‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫¯‬ ‫¯‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‬

‫‪.‬‬ ‫¯‬ ‫(‬ ‫)‬ ‫‪.‬‬

‫‪.‬‬ ‫¯‬ ‫ٕ‬ ‫)‬ ‫‪.‬‬ ‫‪.‬‬

‫‪:‬‬

‫¯‬ ‫‪.‬‬ ‫¯‬ ‫ٕ‬ ‫¯‬

‫(‪.‬‬

‫‪,‬‬

‫¯‬

‫‪.‬‬

‫¯‬

‫‪:‬‬

‫)‬

‫جمعي ة الص حة العالمي ة ع ام ‪ ٢٠٠٥‬ال دول ا عض اء عل ى "النظ ر ف ي تنفي ذ" توص يات‬ ‫(‪.‬‬ ‫)‬ ‫‬ ‫( ) (‪.‬‬ ‫التعاون والتنمية في الميدان ا قتصادي قد بلغت ھذا الھدف‪.‬‬

‫‪90‬‬

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫‪:‬‬ ‫¯‬ ‫‬

‫¯‬

‫¯‬ ‫¯‬

‫¯‬

‫والش بكة ا يبيري ة ا مريكي ة لمؤش رات العل م والتكنولوجي ا‬ ‫‪.‬‬

‫‪:‬‬ ‫و‬

‫‬ ‫‬ ‫‪.‬‬ ‫‬ ‫‪,‬‬

‫‪:‬‬

‫‬ ‫‪G-‬‬

‫‪,‬‬ ‫‪Finder‬‬

‫‪91‬‬

‫‪A65/24‬‬

‫‪Annex‬‬

‫¯‬

‫‪/‬‬

‫(‪.‬‬ ‫‪.‬‬

‫¯‬

‫)‬ ‫‪.‬‬

‫¯‬ ‫‪٦‬‬ ‫‬ ‫‬

‫‬

‫¯‬

‫‪٥‬‬ ‫‬ ‫–‬

‫‪٤‬‬ ‫‬

‫‪٣‬‬ ‫‬

‫‪٢‬‬ ‫)‬ ‫(‬

‫‪١‬‬

‫–‬

‫)‬

‫(‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫)‬

‫(‬

‫–‬ ‫‪( , ) ,‬‬ ‫‪( , ) ,‬‬ ‫‪( , ) ,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪( , ) ,‬‬ ‫‪( , ) ,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪( , ) ,‬‬ ‫‪,‬‬ ‫‪( , ) ,‬‬ ‫‪,‬‬

‫)‬

‫–‬ ‫(‬

‫)‬

‫)‬ ‫(‬ ‫(‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫–‬

‫(‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬

‫(‬ ‫(‬

‫(‬

‫)‬ ‫)‬ ‫)‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫(‬ ‫(‬

‫)‬ ‫)‬

‫‪,‬‬

‫(‬ ‫‪,‬‬ ‫‪,‬‬ ‫(‬

‫)‬ ‫)‬ ‫(‬ ‫¯‬

‫‪,‬‬

‫)‬

‫(‬

‫‪,‬‬ ‫‪,‬‬ ‫‪,‬‬

‫‪,‬‬

‫القياسات الصحية‪ ،‬الدراسة المسحية ‪G- Finder‬‬

‫‪:‬‬

‫‪92‬‬

A65/24

Annex

: . : : .( )

IHME Statistical annex to financing global health, 2011 (http://www.healthmetricsandevaluation.org/sites/default/files/policy_report/2011/FGH_2011_statistical _annex_IHME.pdf, accessed 8 March 2012).

.G- Finder .G- Finder ) :

.(G- Finder .(G- Finder ) : . .(G- Finder

)

: : : : : G- Finder

.G- Finder

. .

¯ . )

. ,

. .(G-Finder

A65/24

Annex

( )

.G-Finder

¯ .

A65/24

Annex

. . : . , ٕ . ¯ ¯ .( ) , . ¯ ¯ ¯

. . .

(

)

¯ .

.G-Finder . G-Finder

G-Finder

. ¯

)

. . /

.http://www.bvgh.org/GlobalHealthPrimer.aspx

A65/24

Annex

G-Finder

. . ¯

. .

: ¯ . . . ¯ ¯ ¯ ¯ ¯ . . ¯

: ¯

: : , . ¯ •

¯ .

•

, •

A65/24

Annex

‫المراجع‬ 1. France: health system review. Health systems in transition, 2010, 12(6). Copenhagen, World Health Organization for the European Observatory on Health Systems and Policies (http://www.euro.who.int/__data/assets/pdf_file/0008/135809/E94856.pdf, accessed 7 March 2012). EWG submission. Innovative Mechanism for R&D for developing countries: Brazil’s proposal. Submitted by Brazil, 2009 (http://www.who.int/phi/Brazil.pdf, accessed 7 March 2012). Jack A. Charity health campaign wound down. Financial Times, 29 February 2012 (http://www.ft.com/cms/s/0/cc407e74-62f1-11e1-9245-00144feabdc0.html#, accessed 7 March 2012, requires registration). Financing global health 2011. Continued growth as MDG deadline approaches. Seattle, WA, Institute for Health Metrics and Evaluation, 2011 (http://www.healthmetricsandevaluation.org/ publications/policy-report/financing-global-health-2011-continued-growth-mdg-deadlineapproaches#/overview, accessed 7 March 2012). Human development report 1999. Globalization with a human face. New York, United Nations Development Programme, 1999 (http://hdr.undp.org/en/reports/global/hdr1999, accessed 7 March 2012). Small arms and global health. Geneva, World Health Organization, 2001 (Document WHO/NMH/VIP/01.1) (http://whqlibdoc.who.int/hq/2001/WHO_NMH_VIP_01.1.pdf, accessed 7 March 2012). Brzoska M. Taxation of the global arms trade? An overview of the issues KYKLOS, 2004, 57(2):149–172 (http://carecon.org.uk/Chula/2004%20Brzoska%20Kyklos.pdf, accessed 7 March 2012). Nugent R, Knaul F. Fiscal policies for health promotion and disease prevention. In: Jamison DT et al., eds. Disease control priorities in developing countries, 2nd edition. Washington, DC, The World Bank, 2006 (http://www.ncbi.nlm.nih.gov/books/NBK11714, accessed 7 March 2012). Closing the gap in a generation: health equity through action on the social determinants of health. Report of the Commission on Social Determinants of Health. Geneva, World Health Organization, 2008 (http://whqlibdoc.who.int/publications/2008/9789241563703_eng.pdf, accessed 7 March 2012). Global status report on noncommunicable diseases 2010. Geneva, World Health Organization, 2011 (http://www.who.int/nmh/publications/ncd_report_full_en.pdf, accessed 7 March 2012). Global Strategy on Diet, Physical Activity and Health. Geneva, World Health Organization, 2004 (http://www.who.int/dietphysicalactivity/strategy/eb11344/strategy_english_web.pdf, accessed 7 March 2012). Prabhat J, Frank JC. The economics of global tobacco control. British Medical Journal, 2000, 321:358–361 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1118333/pdf/358.pdf, accessed 7 March 2012).

10.

11.

12.

A65/24

Annex

13.

Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of noncommunicable diseases. Lancet, 2011, 378. Published online: 29 September 2011 (http://www.destination-sante.fr/IMG/pdf/tobacco.pdf, accessed 7 March 2012). Global strategy to reduce the harmful use of alcohol. Geneva, World Health Organization, 2010 (http://www.who.int/substance_abuse/alcstratenglishfinal.pdf, accessed 7 March 2012). Parliament approves new sweet tax. Uutiset, 17 November (http://yle.fi/uutiset/news/2010/11/parliament_approves_new_sweet_tax_2147416.html, accessed 7 March 2012). 2010

14.

15.

16.

Kelly DB, Frieden TR. Ounces of prevention − the public policy case for taxes on sugared beverages. New England Journal of Medicine, 2009, 360:1805−1808 (http://www.nejm.org/doi/full/10.1056/NEJMp0902392, accessed 7 March 2012). Denmark introduces world's first food fat tax. BBC News, 1 October (http://www.bbc.co.uk/news/world-europe-15137948, accessed 7 March 2012). 2011

17.

18.

Leicester A, Windmeijer F. The “fat tax”: economic incentives to reduce obesity. Briefing note No. 49. London, Institute for Fiscal Studies, 2004 (http://www.ifs.org.uk/bns/bn49.pdf, accessed 7 March 2012). Witter S, Garshong B. Something old or something new? Social health insurance in Ghana. BMC International Health and Human Rights, 2009, 9:20 (http://www.biomedcentral.com/1472-698X/9/20, accessed 7 March 2012). Tax policies on tobacco products in Thailand: the way forward. New Delhi, World Health Organization, 2011 (http://www.searo.who.int/LinkFiles/TFI_TaxPolicies.pdf, accessed 7 March 2012). World health report 2010. Chapter 2: Health systems financing: the path to universal coverage. Geneva, World Health Organization, 2010 (http://www.who.int/whr/2010/10_chap02_en.pdf, accessed 7 March 2012). Leonen M et al. Taxing health risks. Quezon City and Pasig City, University of the Philippines and Health Justice Philippines, 2010 (http://seatca.org/dmdocuments/Taxing%20Health%20Risks% 20Philippines%202010.pdf, accessed 7 March 2012). The solidarity tobacco contribution. A new international health‐financing concept prepared by the World Health Organization. Geneva, World Health Organization, 2011 (http://www.who.int/nmh/events/un_ncd_summit2011/ncds_stc.pdf, accessed 7 March 2012). Spain: health system review. Health systems in transition, 12(4). Copenhagen, World Health Organization for European Observatory on Health Systems and Policies (http://www.euro.who.int/__data/assets/pdf_file/0004/128830/e94549.pdf, accessed 7 March 2012). Honahan P, Yoder S. Financial transactions tax panacea, threat, or damp squib? Policy Research Working Paper 5230. Washington, DC, The World Bank, 2010 (http://ec.europa.eu/taxation_customs/resources/documents/taxation/gen_info/conferences/ taxforum2011/yoder.pdf, accessed 7 March 2012).

19.

20.

21.

22.

23.

24.

25.

A65/24

Annex

26.

Griffith-Jones S, Persaud A. Financial transaction taxes. No publisher, (http://robinhoodtax.org/sites/default/files/Financial%20Transaction%20Taxes%20%20Griffith-Jones%20%26%20Persaud_0.pdf, accessed 7 March 2012).

2011

27.

Matheson T. Taxing financial transactions: issues and evidence. IMF Working Paper WP/11/54. Washington, DC, International Monetary Fund, 2011 (http://www.imf.org/external/pubs/ft/wp/2011/wp1154.pdf, accessed 7 March 2012). Brondolo J. Taxing financial transactions: an assessment of administrative feasibility. IMF Working Paper WP/11/185. Washington, DC, International Monetary Fund, 2011 (http://www.imf.org/external/pubs/ft/wp/2011/wp11185.pdf, accessed 7 March 2012). McCulloch N, Pacillo G. The Tobin tax: a review of the evidence. IDS Research Report 68. Brighton, Institute of Development Studies, 2011 (http://www.ids.ac.uk/files/dmfile/rr68.pdf, accessed 7 March 2012). Monitoring financial flows for health research. Geneva, Global Forum for Health Research, 2008. Abuja Declaration on HIV/AIDS, Tuberculosis and Other Related Infectious Diseases. Document OAU/SPS/ABUJA/3. Organisation of African Unity, 2001 (http://www.un.org/ga/aids/pdf/abuja_declaration.pdf, accessed 13 March 2012). The Abuja Declaration: ten years on. Geneva, World Health Organization, 2011 (http://www.who.int/healthsystems/publications/Abuja10.pdf, accessed 7 March 2012). Moran M et al. G-Finder Report 2011. Neglected disease research and development: is innovation under threat? London, Policy Cures, 2011 (http://www.policycures.org/downloads/g-finder_2011.pdf, accessed on 12 December 2011).

28.

29.

30.

31.

32.

33.

A65/24

Annex

¯ ¯

: .

¯ ¯ . : ¯ ¯ ¯ ( )" ( ) ( ) ¯

()

( ) ". .( ) ٕ ¯ . ¯ . ¯ .

( )

¯ ¯ ¯

¯ . .¯ ¯

100

A65/24

Annex

¯ . ) ¯ . . ¯ . ¯ ¯ .

¯ ¯

(

¯ .

.¯

¯ ¯ .¯ . . . : . ..."

...

(

...

ٕ ... ) ...

( ) "...

: ... ¯ ... ...

. ..." ... ... ... ¯

( ) "...

101

A65/24

Annex

. . : / .( )

/ −

: /

−

. . .

¯ : ¯

¯ . . ..."

102

A65/24

Annex

¯ ¯

(

) ... .

‚

( ) ". ¯ ¯ ¯

. .( )" .

¯ .¯ ¯ ¯

" " " ¯ .( ) ¯ ."

¯ .(

)

) .(

)

¯ ¯ ¯ .

)

. 103

A65/24

Annex

. : " − −

− −

.( .

) ".

−

)

¯ .

¯ ¯

. ¯

. .

(

) .

¯ ¯ . : . /

¯ .

http://www.who.int/rpc/advisory_committee/en/index.html

104

A65/24

Annex

(

)

( ٕ ¯ :

) ¯ . " " "

: ¯ .

¯ .

( )". ¯ : . ¯ ¯ . / ¯ ¯

)

−

. ¯ ٕ − −

/ . " . " . ¯ ¯ ¯ ٕ

−

105

A65/24

Annex

. )"

¯ " . .(

. . .

)

. . .

. .¯ ٕ .

.¯ . / : . /

http://www/who/int/tdr/partnerships/initiatives/essence/en/index.html

: .

http://www/who/int/tdr/partnerships/initiatives/ishreca/en/

106

A65/24

Annex

¯ . .

. ٕ

ٕ ¯

. .

. " " )" " " " " : : ¯ ¯ ¯ " () ( ) ( ) () ( ) . "

( )( .

. .

/ /

http://www.who.int/ictrp/en http://ottawagroup.ohri.ca

107

A65/24

Annex

( )

( )". ٕ ¯ .(

)

. ٕ

.¯ . . . . ¯ . .

)

¯ . .

. .

. /

http://www.iford.org

108

A65/24

Annex

( . .

)

¯ . . . . . . ¯ ¯ ¯ ¯

Finder

G Finder

¯ : ( . . .( . . . ¯ . . . ) •

¯ •

)

. . /

http://www/edctp.org http://www.hrcsonline.net

: :

109

A65/24

Annex

. . .

•

. .

•

¯ . ¯ ¯ . ¯ ¯ . .( ¯ . . . −

¯ ٕ

)

¯ ¯

. .

.G Finder

110

A65/24

Annex

¯ ¯ .

¯ . . ...

. .( : ¯

)

...¯

.( )" ...¯

..."

" .(

" .

)

¯ ¯ :

)

. . ¯ (

111

A65/24

Annex

. . .

. ¯ ¯

¯ ٕ

: ¯ .( ) " . ¯ "

112

A65/24

Annex

•

• •

•

• • • •

• • • • • • • •

• •

¯ "

. ¯ . .

¯ .

113

A65/24

Annex

. ¯ ¯

" " . ¯

¯ ." .

¯ −

− − −

−

¯ :

)¯ ¯

ٕ . ¯

. .

(

•

( )

G Finder

114

A65/24

Annex

. . . ¯ . : ( •

¯ ¯ . . . •

•

. . )

( )

. . . •

. . .

¯ ¯ . ¯

. ¯

: (

)

) ( ¯ .( . 115

−

) ) ٕ

− −

)(

A65/24

Annex

¯ . . . ‚ . ¯ ¯ . ¯ ‚

‚

¯ G Finder G Finder

( )

.1 Global strategy and plan of action on public health, innovation and intellectual 19first World Health Assembly, -Sixty .property− .61.21Resolution WHA ,2008May 24 In document WHA61/2008/REC/1 (Resolutions, decisions and annexes) (http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf, accessed 5 March 2012). 2. Research and development: coordination and financing. Report of the World Health Organization

Expert Working Group on Research and Development Financing. Geneva, World Health Organization, 2010 (http://www.who.int/phi/documents/ewg_report/en/index.html, accessed 5 March 2012). 3. Coordinating arrangements for R&D. WHO Expert Working Group on R&D Financing. Geneva, Health research: essential link to equity in development. Report of the Commission on Health Research

World Health Organization, 2009 (http://www.who.int/phi/Coordinationdoc.doc, accessed 6 March 2012). 4.

for Development. New York, NY, Oxford University Press, 1990 (http://www.hsph.harvard.edu/healthresearch/files/essentiallinktoequityindevelopment.pdf, accessed 6 March 2012). 5. Investing in health research and development. Report of the Ad Hoc Committee on Health Research

Relating to Future Intervention Options. Geneva, World Health Organization, 1996 (http://www.who.int/tdr/publications/tdr-research-publications/investing-in-health/en/, accessed 6 March 2012). 6. The 10/90 report on health research 1999. Geneva, Global Forum for Health Research, 1999

(http://www.isn.ethz.ch/isn/Digital-Library/Publications/Detail/?ots591=0c54e3b3-1e9c-be1e-2c24a6a8c7060233&lng=en&id=20437, accessed 6 March 2012). 7. The Global Forum for Health Research. Corporate and Global Evaluations and Methods. Washington,

DC, The World Bank, 2009 (http://siteresources.worldbank.org/EXTGLOREGPARPROG/Resources/gfhr.pdf, accessed 6 March 2012). 8. Research and the World Health Organization: a history of the Advisory Committee on Health Research

1959–1999. Geneva, World Health Organization, 2010 (http://whqlibdoc.who.int/publications/2010/9789241564113_eng.pdf, accessed 6 March 2012). 9. Terry R, van der Rijt T. Overview of research activities associated with the World Health Organization:

results of a survey covering 2006/07. Health Research Policy and Systems, 2010, 8:25 (http://www.healthpolicy-systems.com/content/8/1/25, accessed 6 March 2012).

116

A65/24

Annex

10.

Kabir ZN, Holmgren J. Overview of research activities at World Health Organization. Stockholm,

Swedish International Development Authority, 2005 (http://www.who.int/rpc/publications/SidaOverview_of_Research_Activites_at_WHO.pdf, accessed 7 March 2012). 11. WHO’s role and responsibilities in health research (resolution WHA63.21). Progress reports. Report by the Secretariat. 130th session of the WHO Executive Board. Document EB130/35, 17 November 2011 (http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_35-en.pdf, accessed 7 March 2012). 12. Viergever RF. Health research prioritization at WHO. An overview of methodology and high level

analysis of WHO led health research priority setting exercises. Geneva, World Health Organization, 2010 (http://www.who.int/rpc/publications/Health_research_prioritization_at_WHO.pdf, accessed 7 March 2010). 13. Viergever RF et al. A checklist for health research priority setting: nine common themes of good

practice. Health Research Policy and Systems, 2010, 8:36 (http://www.health-policysystems.com/content/8/1/36, accessed 7 March 2010). 14. Health research strategy for Health for All by the Year 2000. Report of a bub-committee of the ACHR.

(Advisory Committee on Health Research document WHO/RPD/ACHR (HRS)/86). Geneva, World Health Organization, 1986 (http://www.who.int/rpc/advisory_committee/ACHR-Health_Research_Strategy(1986).pdf, accessed 7 March 2012). 15. A research policy agenda for science and technology to support global health development. (Advisory

Committee on Health Research document WHO/RPS/ACHR/98.1). Geneva, World Health Organization, 1998 (http://whqlibdoc.who.int/hq/1998/WHO_RPS_ACHR_98.1.pdf, accessed 7 March 2012). 16. Genomics and world health. Report of the Advisory Committee on Health Research. Geneva, World Ten year vision and strategy. (Document TDR/GEN/06.5/EN/Rev.2). Geneva, Special Programme for

Health Organization, 2002 (http://whqlibdoc.who.int/hq/2002/a74580.pdf, accessed 7 March 2012). 17.

Research and Training in Tropical Diseases, 2007 (http://whqlibdoc.who.int/hq/2006/TDR_GEN_06.5_EN_Rev.2_eng.pdf , accessed 7 March 2012). 18. Nwaka, S. Integrated regional and global coordination and financing mechanism of R&D for diseases

that disproportionately affect developing countries - the ANDI model. http://www.who.int/phi/news/phi_14_cewg_en.pdf, accessed on 4 November 2011) 19. Planning, monitoring and evaluation framework for capacity strengthening in health research. Geneva,

ESSENCE on Health Research, 2011 (http://whqlibdoc.who.int/hq/2011/TDR_essence_11.1_eng.pdf, accessed 7 March 2012). 20. WHO’s role and responsibilities in health research Sixty-third World Health Assembly, 17−21 May

2010, Resolution WHA 63.21. (http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R21-en.pdf, accessed 7 March 2012). 21. WHO’s role and responsibilities in health research: Draft WHO strategy on research for health. Sixty-

third World Health Assembly, 17−21 May 2010, Document A63/22 (http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_22-en.pdf, accessed 7 March 2012). 22. Report on financial and administrative implications for the Secretariat of resolutions proposed for

adoption by the Executive Board or Health Assembly. Sixty-third World Health Assembly, 17−21 May 2010, Document A63/22 Add.129 (http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_22Add1-en.pdf, accessed 7 March 2012).

117

A65/24

Annex

23.

Viergever R. Aid alignment for global health research: the role of HIROs. Health Research Policy and Health research classification systems – Current Approaches and Future Recommendations. Science

Systems, 2011, 9:12 (http://www.health-policy-systems.com/content/9/1/12, accessed 7 March 2012). 24. Policy Briefing 43. Strasbourg, European Science Foundation, 2011 (http://www.esf.org/fileadmin/FlipBooks/emrc_spb43/emrc_sbp43/assets/downloads/SPB_43_Nov2011.pdf, accessed 7 March 2012). 25. DAC members aid performance in 2010. Annex A in: Development co-operation report 2011. Paris,

Organisation for Economic Co-operation and Development, 2011 ( http://www.oecdilibrary.org/development/development-co-operation-report-2011_dcr-2011-en, accessed 13 March 2012). 26. World development report 1993: investing in health. Washington, DC, The World Bank and New York,

NY, Oxford University Press, 1993 (http://wdronline.worldbank.org/worldbank/a/c.html/world_development_report_1993/chapter_7_agenda_action , accessed 7 March 2012). 27. Macroeconomics and health: investing in health for economic development. Geneva, World Health Bringing together the best of science and the best of development. Independent Review of the CGIAR

Organization, 2001 (http://whqlibdoc.who.int/publications/2001/924154550X.pdf, accessed 7 March 2012). 28.

System. Technical Report. Washington, DC, Consultative Group on International Agricultural Research, 2008 (http://www.cgiar.org/pdf/agm08/agm08_CGIAR-technical-report.pdf, accessed 7 March 2012). 29. Sagasti F, Timmer V. An approach to the CGIAR as a provider of international public goods.

Washington, DC, Consultative Group on International Agricultural Research, 2008 (http://www.cgiar.org/pdf/ir_sagasti_timmer.pdf, accessed 7 March 2012).

118

A65/24

Annex

¯ . "

" ¯

: : . . . . . . . . . . . . ¯ ¯ RED

¯ ¯

. ¯ .

•

119

A65/24

Annex

. ¯

ٕ " "

¯ . .

–

. .

¯ .

: ¯ . . . . ¯ ) . " – ¯ ¯ ¯ . 120

– (

A65/24

Annex

¯ ¯ ) ¯ " . " . " ¯ ¯ " . . ¯ " " . . " ¯ " " ¯ " . " . " . ٕ . " .

" .

¯ ¯ ¯

" " " .

121

A65/24

Annex

: ( ¯ )

−

. / . ¯

−

ٕ ¯

¯ , , )

, . , , .

: (

−

122

A65/24

Annex

.¯ . . . ¯

¯ ¯

. .

.( ) . : • •

• •

. ¯ "

•

123

A65/24

Annex

.( ) " .

¯ ¯

" "

¯ . ¯ . – . . ¯ . –

: . ¯ ¯ ٕ . ¯ ¯ ¯

¯ .

.( ) " ¯ . ¯ : / ¯ ..."

. : ¯ .

124

A65/24

Annex

()

( ) ¯ ( )

() . ¯ ٕ . ¯ ( ) . . ( )

( )

.( ) "

¯ .( .

.( )

– )

125

A65/24

Annex

. .

–

. .

: •

•

. . : • •

•

. . . . ¯ – : http://www.who.int/fctc/text_download/en/index.html.

¯ / ¯ ¯ . / ¯

•

¯ :

126

A65/24

Annex

. ¯ ¯ ( . ) ( ¯ ) .

¯ ¯

ٕ .

. .

ٕ :

: http://unfccc.int/kyoto_protocol/items/2830.php.

¯ . ¯

. . ¯ ¯ . ¯ . " ¯ " .

. .

/ /

http://www.wto.org/english/thewto_e/whatis_e/tif_e/disp1_e.htm

: http://www.thegef.org/gef/whatisgef

¯ ¯

http://www.ohchr.org/EN/HRBodies/Pages/ HumanRightsBodies.aspx

127

A65/24

Annex

(

)

¯ ¯ "

.( ) "

¯ . ¯ ¯

¯ ¯ . ¯ .( .

)

.( )

http://www.adaptation-fund.org

128

A65/24

Annex

¯ ¯

ٕ ٕ . ¯ ¯ . . ¯ . . ¯

. ¯

¯ ¯ ¯ ¯ . . .

¯ , ¯

. .

. ( ) .¯ / : www.multilateralfund.org

(

) , (

) ¯ (

: ) )

( /

¯ (

) ( .

) .( : .

)

http://unfccc.int/2860.php

129

A65/24

Annex

.("

ٕ ¯

" ¯ "

" ¯ .

)

" "

¯ "

)

(

. ¯ ¯ " .

¯ .

" ,

¯ "

.( ) " " .( " " )" " ¯ ¯

.( )

.( ) " .

¯ ¯ (

.( )

. .¯ .( ) )

¯ http://www.unicef.org nutrition/index_24805.html

130

A65/24

Annex

: ٕ . . : ¯ . ¯ . − − •

• •

¯ . : ¯ ¯

− −

−

ٕ . . . ) ) .( ¯

− − −

. ( ) ( ( ( ) ) . : ) .( )

. ( ( (

)

http://whqlibdoc.who.int/hq/1999/WHO_NCD_TFI_99.4.pdf) www.who.int/entity/fctc/reporting/progress_report_final.pdf)

.WHO/NCD/TFI/99.4

(

131

A65/24

Annex

. . .

( )

( ) . .(

( )

(

)

) ¯ .

: ¯ ¯

/ −

. .

−

¯ : . ".

. "

132

A65/24

Annex

. .

. : : ٕ ¯ " () ( ) ( ) () ( )

". ¯ . : ". . . ٕ . ¯

. "

. ¯ ¯

133

A65/24

Annex

¯ . : ¯ ¯ ( )"

( ) ( ) () ( )

¯ ٕ

( ) ( ) ( )

.( . ¯ ¯ . ¯

134

A65/24

Annex

¯ ¯ . (

( :

( ¯

¯ •

•

• •

•

. ¯

•

135

A65/24

Annex

. . . . ¯ . ¯ . ¯ . . .

•

¯ ") .(" . ¯ ¯ ¯ . . •

•

. ¯ .

¯ : 136

A65/24

Annex

¯ ¯ ¯ . . . ¯ ¯

•

¯ .

•

WHO’s role and responsibilities in health research: Bamako Global Ministerial Forum on Research for Health. Report by the Secretariat. 124th Session of the WHO Executive Board, Document EB124/12 Add.2, 6 January 2009 (http://apps.who.int/gb/ebwha/pdf_files/ EB124/B124_12Add2-en.pdf, accessed 6 March 2012). Council conclusions on the EU role in global health. 3011th Foreign Affairs Council meeting. Brussels, Council of the European Union, 2010 (http://www.consilium.europa.eu/uedocs/cms_Data/docs/pressdata/EN/foraff/114352.pdf, accessed 6 March 2012). Simmons BA, Mobilizing for human rights. Cambridge, Cambridge University Press, 2009. Framework Convention on Climate Change. Report of the Conference of the Parties on its sixteenth session. Cancun 29 November to 10 December 2010. Document FCCC/CP/2010/7/Add.1, March 2011 (http://unfccc.int/files/na/application/pdf/07a01-1.pdf, accessed 6 March 2012). Financial status of the Adaptation Fund Trust Fund. Document AFB/EFC.8/7 14. Bonn, Adaptation Fund, 2012 (http://www.adaptation-fund.org/sites/default/files/AFB.EFC_.8.7% 20Financial%20Status%20of%20the%20AF%20Trust%20Frund.pdf , accessed 6 March 2012). The 0.7% target: an in-depth look. New York, The Millennium Project, 2006 (http://www.unmillenniumproject.org/press/07.htm, accessed 6 March 2012). DAC members aid performance in 2010. Annex A in: Development co-operation report 2011. Paris, Organisation for Economic Co-operation and Development, 2011 (http://www.oecdilibrary.org/development/development-co-operation-report-2011_dcr-2011-en, accessed 13 March 2012). International Code of Marketing of Breast-milk Substitutes. Geneva, World Health Organization, 1981. (http://www.unicef.org/nutrition/files/nutrition_code_english.pdf, accessed 6 March 2012).

3. 4.

137

A65/24

Annex

Beigbeider Y. L’Organisation Mondiale de la Santé. Paris, Presses Universitaires de France, 1995. Casswell S, Thamarangsi T. Reducing harm from alcohol: call to action. The Lancet, 2009, 373: 2247−2257. Sridhar S. Regulate alcohol for global health. Nature, 2012, 482:16. Editorial. Urgently needed: a framework convention for obesity control. The Lancet, 2011, 378:741. Editorial. Fighting fake drugs: the role of WHO and pharma. The Lancet, 2011, 377: 1626. Oxman AD et al. A framework for mandatory impact evaluation to ensure well informed public policy decisions. The Lancet, 2010, 375: 9712. Lawrence OG et al. The joint action and learning initiative on national and global responsibilities for health. World health report (2010) Background Paper, No 53. Geneva, World Health Organization, 2010 (http://www.who.int/healthsystems/topics/financing/healthreport/53JALI.pdf, accessed 6 March 2012). Hoffman SJ, Røttingen JA. A framework convention on obesity control? The Lancet, 2011, 378:2068. Global strategy and plan of action on public health, innovation and intellectual property. Sixty-first

10.

11. 12.

13. 14.

15.

16.

17.

World Health Assembly, 19−24 May 2008, Resolution WHA61.21. In: document WHA61/2008/REC/1 (Resolutions, decisions and annexes) (http://apps.who.int/gb/ebwha/ pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf, accessed 5 March 2012)

138

A65/24

Annex

¯ ¯ : ( ) (

¯ ¯ ) ( ( ( ) ) ) ¯ ¯ . . .

/ ( • • • •

)

. .

¯ "

. ¯ " .

)

http://www.who.int/phi/news/cewg_2011/en/index.html

139

A65/24

Annex

" ¯ ¯

¯ .

¯ ¯

¯ ¯ ¯ ¯ ¯ ¯ ¯ ¯ ¯ ¯ ¯ . ¯ ) . /

( ¯

¯ :

• •

. ٕ . ( ¯ ( ) ) ¯ .( ( ) ( ) ٕ ( ) .( / / /

•

)

140

A65/24

Annex

.¯ ) ¯

¯ ¯ ¯ ( ¯

. .¯

¯ . ¯

¯ ¯ . ¯ ¯ ¯

/ . / . . ¯

: ¯ ¯ ¯

¯ •

. ¯ ¯ ¯

•

¯ ¯ . ¯ EWG”

www.who.int/phi/explanation_of_methodology_used_by_the_EWG.pdf ”Methodology Used by the

141

A65/24

Annex

) . ¯ ¯ ¯ . ¯

¯ . ¯

¯ ¯ .

¯ ( ¯ ¯

. • • • • • • • • • • •

•

¯ ¯ .

¯ ¯

¯ ..

. 142

A65/24

Annex

. ¯ )¯ ¯

¯ ¯

.( ¯ ¯ ¯ ¯

¯ / ¯ ¯

) . . ٕ ¯

¯ ( ¯

. ¯

. . .¯ ¯ ¯ ¯

¯ . . ¯

(¯ ¯

¯ . "

)

.¯

" "

143

A65/24

Annex

¯ :

/ :

(¯ .

) ¯ /

¯ / .

http://www.who.int/phi/mspublichearing_rdf/en/index.html.

: http://www.who.int/phi/shpublichearing_rdf/en/index.html.

: ¯

¯ .

¯ −

− −

( ) .( )

( ) ¯ / ¯

Innovative financing for global health: tools for analyzing the options

.¯ ¯

¯ ¯

IGWG public hearing – proposals recommendations

.http://www.who.int/phi/news/cewg_proposals/en/index.html :

¯ 144

A65/24

Annex

)

http://www.who.int/phi/inventory_of_proposals.xls

.(missions alphabeticallyAll sub

: ¯ ) " ) " " ( .( ) .

." ) .(

¯ (

Inventory ¯ ¯ .¯ . ٕ ¯ .

http://www.who.int/phi/public_hearings/ewg_2ndhearing_reldocs/en/index.html

¯ .

¯ ¯ : :

. . ¯ ¯

http://www.who.int/phi/public_hearings/ewg_2ndhearing_reldocs/en/index.html.

http://www.who.int/phi/public_hearings/second/contributions/mspublichearing_rdf09/en/index.html.

: http://www.who.int/phi/public_hearings/second/contributions/shpublichearing_rdf09/en/index.html.

145

A65/24

Annex

¯ : "List of submissions to second hearing of EWG – not in inventory"

http://www.who.int/phi/news/cewg_proposals/en/index.html

: ¯ . . Inventory of 22

(

. ¯

)

¯ " (Grouped proposals . . C ) A : ) ¯ .

http://www.who.int/phi/news/cewg_proposals/en/index.html

ٕ "grouped proposals ¯

¯ "Sources"

¯ D E

.(F)

B (A) .

.¯

¯ F

(Reading list

¯ ) "Inventory proposals not accounted"" (http://www.who.int/phi/news/cewg_proposals/en/index.html : .¯ ¯ F ¯ ¯ ¯ "Sources" ¯ (Reading list . )

. . ¯

146

A65/24

Annex

¯ ¯ .¯ / ¯

¯ ¯ ¯ ¯ .

. ¯ ¯

¯ ( ¯ ) ( )

( ) ( )

(

) ¯

( )

(

)

( ¯

) ¯

( . ¯

)

147

A65/24

Annex

(

)

" ( ( ) )

¯ . / ¯

¯ ¯ ¯ ¯ ¯ ¯ .¯

¯ ¯ .

.http://www.who.int/phi/news/cewg_submissions/en/index.html : ¯ ¯ ( − ) . ) ( . )

: ¯ . .¯

(

−

148

A65/24

Annex

¯ ¯ .

¯ .

. ٕ

. .

.Internationales et du Développement .

¯ Institut de Hautes Études .(

)

. .

" "

.BIO Ventures for Global Health UKO Pharma- all med / Kampagne. Charité Universätmedzin Berlin. Universität Oldenburg.

. .

149

A65/24

Annex

¯ ¯

¯ . .

.(Incentives for Global Health)

. ¯

. ¯ .Health Insight Ltd . .

¯ ¯ . ¯ ¯ . .

Clinical Research, Dr Agarwal's Eye Hospital Ltd.

. Clinical Research, Dr Agarwal's Eye Hospital Ltd.

. Euromed Management, Centre National de la Recherche Scientifique, Groupement de Recherche en Economie Quantative d’Aix . . Marseille, (IDEP)

.Euromed Management . .

150

A65/24

Annex

¯ ¯ . . ¯ ¯ " " . ¯

: ¯ ¯ .

¯ .

¯ ¯ ¯ ¯

: : . .

¯ . ¯

. . . ٕ

: .( ¯ . .( ) ) ¯ )

(

151

A65/24

Annex

: : : ."

¯ ¯

¯ ¯ "

: . . .

¯ : . : : .( ¯ ) . ¯ .

: : .

¯ ¯ : : ¯ .

)

) ¯ : ¯ "

¯ ¯

)

: : .(Incentives for Global Health) : ( ¯ )

¯ ¯ "

¯ . : ¯ ¯

152

A65/24

Annex

: : : ."( ."

¯ ¯ " . (

)

¯ ¯ ¯ ¯ " "

)

: : . . "

. . ٕ

. )

: : ¯ " " "

(

¯ ."

: .

¯ .

UKO Pharma-Kampagne. Charité Universätmedzin

.all4med / Berlin. Universität Oldenburg

. . .( ¯

: :" ) "

153

A65/24

Annex

: " "

¯ " " . ¯

: " BIO Ventures for Global

¯ " . .

Health.

: . . .( .(

¯ ¯ ٕ

) ) )

¯ ¯ ¯ .

/ (

) .( . ¯ .( ¯

(

) ¯ ¯ )

.( ¯ ¯

¯ ) )

) (Knowledge Ecology International) . . ¯ .( ¯

154

A65/24

Annex

: "

¯ "

: : "

¯ . ¯ "

: :

¯ .

¯ " " .

: : : : :

¯ ¯ . ¯

¯ .

¯ . ¯

¯ .

(

" .

155

A65/24

Annex

Public health, innovation and intellectual property rights. Commission on Intellectual Property Rights, Innovation and Public Health. Geneva, World Health Organization, 2006 (http://www.who.int/intellectualproperty/report/en/index.html, accessed 5 March 2012). Taskforce on Innovative Financing for Health Systems (2009). Raising and channeling funds. Working Group 2 report. http://www.internationalhealthpartnership.net/en/taskforce, accessed 5 March 2012). De Ferranti D et al. (2008). Innovative financing for global health: tools for analyzing the options. Washington, DC, Brookings Institution, 2008 (Global Health Financing Initiative, Working Paper 2).

156

A65/24

Annex

¯ :( ) . (All

. ٕ

India Drug Action)

. . . ¯

: .

¯ .

¯ : 157

A65/24

Annex

–

−

( )" " –" ¯

" −

" .( ) "

.( )

. ¯ . ٕ . .

( )

( ) ( ) ( )

¯ ¯ ( )

158

A65/24

Annex

( )

( ) ( ) ( ) ( ( ) )

. :

( ) ¯ ( )

( : ) () ( ) ¯ ) 159

( )

A65/24

Annex

(

. ( )

()

( ) ( ) ( ) ( ) ) ( ( )

( ) : ¯ ¯ ٕ () ( ) ( ) ( )

160

A65/24

Annex

() ( ) ( )

¯ ¯ . ( ( ٕ (

( ) )

) )

.( )

( .

)

. ٕ

. :¯

. ¯

161

A65/24

Annex

. . . ( ) . / :

•

. •

. . . . ¯

" ." . : . 162

•

A65/24

Annex

¯ . : :

: . ¯ ¯ ¯ ¯

•

. . : . )

¯ ¯

( )

. (

( ) . ( ( ) / . ( ) )

. ¯ .

( )

( ) ¯ .

163

A65/24

Annex

. / .¯

. .

( )

. . . ٕ ¯ ) . ( ¯

. ( . (

( )

)

) .

−

.( )

−

164

A65/24

Annex

. ." ": ٕ " . ( ) ¯ ( ) ¯ ": " ¯

.( ) "

" .( ) "

" ." ٕ

. ¯ 165

A65/24

Annex

¯ .

.( )

. " ( ) ... : ¯ .

.( ) " ¯ ¯ .

. . .

166

A65/24

Annex

¯ ¯ . . ¯ . ¯ . . . . . . /

CEWG submission. Consideration of an essential health and biomedical R&D treaty. Submitted by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, and Third World Network, 2011 (http://www.who.int/phi/news/phi_1_rd_submissiontemplate_en.pdf, accessed 8 October 2011). CEWG submission. A global framework on health research and development. Submitted by All India Drug Action Network, Berne Declaration, CENTAD, Initiative for Health and Equity in Society, People’s Health Movement, and Third World Network, 2011 (http://www.who.int/phi/news/phi_19_submission_cewg_en.pdf, accessed 8 October 2011). CEWG submission. Comments by HAI Global. Submitted by Health Action International (HAI) Global, HAI Latin America and the Caribbean (AISLAC) and HAI Europe (HAI-E), 2011 (http://www.who.int/phi/news/phi_17_health_action_int_sub_en.pdf, accessed 8 October 2011). EWG submission. Submission of Third World Network. Submitted by Third World Network, 2009 (http://www.who.int/phi/public_hearings/second/contributions/SangeetaShashikantThirdWorld Network.pdf, accessed 8 October 2011).

167

A65/24

Annex

EWG submission. Proposal for WHO discussions on a biomedical R&D treaty. Submitted by Bangladesh, Barbados, Bolivia and Suriname, 2009 (http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_R_DTreaty.pdf, accessed 8 October 2011). EWG submission. Health Action International response: response to the Expert Working Group on Alternative Financing. Health Action International, 2009 (http://www.who.int/phi/HAI.pdf, accessed 8 October 2011). EWG submission. Comments of Knowledge Ecology International (KEI) to the WHO public hearing for proposals for new and innovative sources of funding to stimulate R&D. Knowledge Ecology International, 2009 (http://www.who.int/phi/KEI.pdf, accessed 8 October 2011).

. ¯

¯ .

¯ (

) . . ( ¯ .

. ¯ .

.( )

)

. ¯

. . .

168

A65/24

Annex

. . . . ¯ ¯

Health Affairs .( ) ( ¯ ( ¯ ¯

¯ ) ¯ ) ) ¯

( )

¯ . ¯ ¯

. .

.( ) . (

¯ . ) ¯

.( ) .( )

.( )

169

A65/24

Annex

.¯

¯ .

¯ ¯ . . ¯ . . . ¯ ( )¯ . ¯ /

170

A65/24

Annex

Clift C. Data protection and data exclusivity in pharmaceuticals and agrochemicals. In: Krattiger A et al. eds. Intellectual property management in health and agricultural innovation: a handbook of best practices. London, Concept Foundation, PIPRA, FIOCRUZ and bioDevelopments-Int. Institute, 2007 (http://www.iphandbook.org/handbook/chPDFs/ch04/ipHandbookCh%2004%2009%20Clift%20Data%20Protection%20and%20Exclusivity.pdf, accessed 9 October 2011). Goldman D et al. The benefits from giving makers of conventional “small molecule” drugs longer exclusivity over clinical trial data. Health Affairs, 2011, 30(1):84−90 (http://content.healthaffairs.org/content/30/1/84.short, accessed 9 October 2011). Correa C. Protection of data submitted for the registration of pharmaceuticals: implementing Geneva, South Centre, 2002 the standards of the TRIPS agreement. (http://apps.who.int/medicinedocs/pdf/h3009ae/h3009ae.pdf, accessed 9 October 2011). All costs, no benefits: how TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines. Oxfam Briefing Paper, Oxford, Oxfam International, 2007 (http://donttradeourlivesaway.files.wordpress.com/2011/01/all-costs-no-benefits.pdf, accessed 9 October 2011).

(

¯ ) :

¯ . . : . : :

Concept note. Innovative financing mechanism for global health

¯ .

innovation.

171

A65/24

Annex

ٕ . . ¯ ) ¯ . ¯ ( ) (

)

. ¯

, .( ) "

( " " . −

.( ) ( . . ¯ , (R&D for Affordable Healthcare)

) .

.( )

.( ) :

¯ ¯ •

.( ) . •

.( ) ¯ ¯ ¯

.( )"

" 172

A65/24

Annex

)

.( ) "

(

) .(

/ . )

¯ ¯ ¯ .

(

) (

.( )

173

A65/24

Annex

¯ ¯ . . . . . ." ¯ . . . " . /

CEWG submission. New investment strategy: innovative developing country research awards. Submitted by Global Forum for Health Research. (http://www.who.int/phi/news/phi_5_new_investmt_strat_SBIR_model_en.pdf, accessed 10 October 2011). £45 million initiative to support development of affordable healthcare products. London, Wellcome Trust (press release, 29 July 2010) (http://www.wellcome.ac.uk/News/Mediaoffice/Pressreleases/2010/WTX060350.htm, accessed 10 October 2011). IAVI’s innovation fund to bring novel early-stage technologies to AIDS vaccine research: flexible and rapid-response funding for pioneering ideas. London, Department for International Development, (http://www.dfid.gov.uk/R4D/PDF/Outputs/iavi/iavifactsheetinnovation.pdf, accessed 10 October 2011). CEWG submission. A new incentive system for technological innovation in developing countries. Submitted by Maito MA and Franciosi E. (http://www.who.int/phi/news/cewg_2011/en/index.html, accessed 10 October 2011). New Gates funding will enable MVI and GSK Biologicals to complete development of world’s most advanced malaria vaccine candidate. Bethesda, MD, PATH Malaria Vaccine Initiative, and London, GlaxoSmithKline Biologicals (press release, 31 October 2005)

174

A65/24

Annex

(http://www.path.org/news/pr-051027-malaria-vaccine-candidate.php, accessed 10 October 2011). 6. European and Developing Countries Clinical (http://www.edctp.org, accessed 10 October 2011). Trials Partnership (EDCTP), 2011

Wessner CW. EWG submission. Concept note. Innovative financing mechanism for global health innovation. US National Academies of Science, with support from the Global Forum for Health Research 2009 (http://www.who.int/phi/SBIR.pdf, accessed 10 October 2011).

. ¯

¯ . : .

:( .

)

. ¯

¯ :

" ":

(

) ¯

¯ " .

" .

. ¯ ¯

, ¯

.( )

175

A65/24

Annex

. .

.( )

¯ ¯ ¯ ¯ . ¯

. . ¯

¯ .

.( ) ¯

. ) ¯ . .¯ ¯

. ( ) ¯ .

.( )

(

176

A65/24

Annex

¯ ¯ . . . . . . . . . , /

Nitta I. CEWG submission. International Fund for Innovation (IFI): an innovative financing mechanism for medicines in the developing world 2011 (http://www.who.int/phi/news/phi_13_who_itaru_en.pdf, accessed 11 October 2011). International Bank for Innovation: a paradigm shift in global intellectual property legitimacy. Geneva, Green Intellectual Property Project, 2010 (http://www.greenip.org/files/_60_IBI.doc, accessed 11 October 2011). Nitta I. EWG submission. Patent insurance (Green Intellectual Property) scheme: a financial prescription for neglected diseases? Geneva, Green Intellectual Property Project, 2009 (http://www.who.int/phi/GreenIP.pdf, accessed 11 October 2011). Nitta I. CIPIH submission. Patents and essential medicines: an application of the Green Intellectual Property Project 2005 (http://www.who.int/intellectualproperty/submissions/ITARUNITTA.pdf, accessed 11 October 2011).

177

A65/24

Annex

¯ . ¯ :

¯ .Incentives for Global Health

. ¯

.¯

¯ . .¯ ¯ ¯ ¯ ¯ . ¯ ¯ ¯ . ¯ . ¯ ¯ ¯ . . .

. ¯ ¯

178

A65/24

Annex

. ¯ . . ¯ .

.( ) ¯

¯ .

. .

ٕ . . . ¯ ¯

¯ . .¯

¯ . ¯ .

¯ ) ¯ . ¯

¯ ¯ ¯

.( ) 179

A65/24

Annex

( ٕ

) ¯

.( . . . .

)

. , .

¯ .

. .

, ¯ ¯

, .

.( ) " .( ) ٕ ."¯ . "¯ ¯

. ¯ ¯

.( ) .( )

.( )

180

A65/24

Annex

. , ¯

.( )

¯ .

. ¯ ¯

¯ ¯ .¯ . . . ¯ . . . . .

181

A65/24

Annex

Hollis A, Pogge T. The Health Impact Fund: making new medicines accessible to all. New Haven, CT, Incentives for Global Health, 2008 (http://www.yale.edu/macmillan/igh/hif_book.pdf, accessed 11 October 2011). Sonderholm J. A reform proposal in need of reform: a critique of Thomas Pogge’s proposal for how to incentivize research and development of essential drugs. Public Health Ethics, 2009, 3:167−177. CEWG submission. Health Impact Fund. Submitted by Incentives for Global Health, 2011 (http://www.who.int/phi/news/phi_7_cewg_hif_submission_jun2011_en.pdf, accessed 11 October 2011). Love J. HIF in the European Parliament. Geneva, Knowledge Ecology International, (blog post, 11 April 2011) (http://keionline.org/node/1112, accessed 11 October 2011). Institute for Health Metrics and Evaluation. Financing global health 2010: development assistance and country spending in economic uncertainty. Seattle, University of Washington, 2010 (http://www.healthmetricsandevaluation.org/sites/default/files/policy_report/2010/FGH_2010_ REPORT_FINAL_051111.pdf, accessed 11 October 2011). IMS Health forecasts global pharmaceutical market growth of 5-7 percent in 2011, reaching $880 Billion. Danbury, CT, IMS Health (press release, 6 October 2010) (http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c2 2a/?vgnextoid=119717f27128b210VgnVCM100000ed152ca2RCRD&vgnextchannel=41a6790 0b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default, accessed 11 October 2011). Pogge T et al. EWG submission. The Health Impact Fund: pay-for-performance, 2009 (http://www.who.int/phi/HIF.pdf, accessed 11 October 2011).

182

A65/24

Annex

( .

) ¯

¯ .

(

)

. ¯ ¯

.¯ . ¯ ¯

( )

.( ) ¯

.¯ .( )

. 183

A65/24

Annex

.( ) /

ٕ .

.( / ¯

) ¯ ¯ .

. .

.( ¯ (

) .( ) " "

) .

. .¯

¯ " " ¯ ¯

. .

" ¯

. 184

)

A65/24

Annex

: ¯

¯ −

−

/ . . ¯ ¯ . . . " "

− −

. ¯

. /

¯ .( ) .

185

A65/24

Annex

¯ . . . ¯ ¯ . . . . . . ¯

(

)

Cote T, Xu K. Accelerating orphan drug development. Nature Reviews Drug Discovery, 2010, 9:901−902 Braun MM et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nature Reviews Drug Discovery, 2010, 9:519–522 (http://medpediamedia.com/media/1019/Emergence_of_orphan_drugs_in_US.pdf, accessed 12 October 2011). Grabowski H. Increasing R&D incentives for neglected diseases – lessons from the Orphan Drug Act (unpublished data, 2003) (http://econ.duke.edu/Papers/Other/Grabowski/Orphan_Drug.pdf, accessed 12 October 2011). Villa S, Compagni A, Reich MR. Orphan drug legislation: lessons for neglected tropical diseases. International Journal of Health Planning and Management, DOI:10.1002/hpm, 2008 (http://www.wcfia.harvard.edu/sites/default/files/Reich_Orphan.pdf, accessed 12 October 2011). Milne C, Kaitin K, Ronchi E. Orphan drug laws in Europe and the US: incentives for the research and development of medicines for the diseases of poverty. Commission on Macroeconomics and Health, Working Paper Series, Paper No. WG2:8, 2001 (http://www.emro.who.int/cbi/PDF/OrphanDrugLaws.pdf, accessed 12 October 2011).

186

A65/24

Annex

Trouillier P et al. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts. Tropical Medicine and International Health, 4(6):412–420, 1999 (http://onlinelibrary.wiley.com/doi/10.1046/j.1365-3156.1999.00420.x/pdf, accessed 12 October 2011). Silverman E. KV Pharma & the Orphan Drug Act: Jamie explains (blog post on Pharmalot Blog, 23 March 2011) (http://www.pharmalot.com/2011/03/kv-pharma-and-the-orphan-drugact-jamie-explains/, accessed 12 October 2011). Mckee S. Close legal loophole allowing high-cost orphan drugs, doctors say. Pharma Times, 2010 (http://www.pharmatimes.com/Article/10-11-18/Close_legal_loophole_allowing_highcost_orphan_drugs_doctors_say.aspx, accessed 12 October 2011).

((

)

¯ ) :

¯ ¯

.( . " " ) ¯ " /

" (Re:search)

" ¯ 187

A65/24

Annex

)

.( ) .

. . . . . / ¯ ¯

.( )

ٕ ¯ ¯

.( ) . ¯ .

188

A65/24

Annex

. . . ¯ . ¯ ) . ¯ ( ¯ .

. ٕ

. ¯ ٕ

¯ .

.( "

)

.( )

189

A65/24

Annex

" ¯ " − − − − − − −

" "

. . " . " " " " " " " " " ¯ " " " " ) " " " ¯ " ¯

¯ " " . " "

−

" ¯

( .

) )

( (PATH

190

A65/24

Annex

. ¯ .

. :

(

)

( ) ". " ¯ .

. .

. " ¯ ¯

¯ ¯ " ¯

¯ . .

.( ) "

191

A65/24

Annex

" ٕ . . ٕ

/ ¯ ¯ ٕ

. )

¯ (

¯ . .

. ¯

.( ) ¯ ¯ ٕ .

" "

.( )

. ¯

¯ (

.( )

)

" . 192

A65/24

Annex

" ¯ .

. .

¯ ¯ . . ¯ . ¯ ¯ ¯ /

¯ ¯

. . . .

. . . . ¯ .

. .

193

A65/24

Annex

Uniting for universal access: towards zero new HIV infections, zero discrimination and zero AIDS-related deaths (Document A/65/797). New York, United Nations, 2011 (http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/A-65797_English.pdf, accessed 12 October 2011). Report on the global AIDS epidemic 2010. Geneva, UNAIDS, (http://www.unaids.org/globalreport/Global_report.htm, accessed 12 October 2011). 2010

Medicines Patent Pool, UNITAID and the WHO HIV/AIDS department. Updated list of missing drug formulations for HIV treatment to be reviewed by the WHO 18th Expert Committee On The Selection And Use Of Essential Medicines. Geneva, World Health Organization, 2011 (http://www.who.int/selection_medicines/committees/expert/18/policy/policy4/en/index.html, accessed 12 October 2011). Medicines Patent Pool, 2011. (http://www.medicinespatentpool.org, accessed 12 October 2011). Waning B et al. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Globalization and Health, 2010, 6(9):1−19, (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883977, accessed 12 October 2011). Pool for Open Innovation, 2011. (http://www.ntdpool.org, accessed 12 October 2011). Goulding R, Palriwala A. Patent pools: assessing their value-added for global health innovation and access. Washington, DC, Results for Development Institute, 2011 (http://healthresearchpolicy.org/assessments/patent-pools-assessing-their-value-added-globalhealth-innovation-and-access, accessed 12 October 2011). Concerns about the process, principles of Medicines Patent Pool and the license. International Treatment Preparedness Coalition October 2011 (http://www.petitionbuzz.com/petitions/mppunitaid, accessed 12 October 2011). DNDi joins WIPO open innovation platform but calls for more ambitious provisions for innovation and access (press release, October 2011). (http://www.dndi.org/press-releases/995wipo.html, accessed 29 February 2012). UNITAID patent pool initiative: implementation plan UNITAID, 2009 (http://www.medicinespatentpool.org/content/download/215/1231/version/1/file/ForWebsite_U NITAID_Patent_Pool_Implementation_Plan_-_Executive_Summary.pdf, accessed 12 October 2011).

4. 5.

6. 7.

10.

194

A65/24

Annex

¯ . . ٕ (All India Drug Action) . .

. .

¯ :

( ) ( ) ¯ ¯ " ¯ " . ¯

−

.( ¯

) "

−

.( ) "

195

A65/24

Annex

.( ) "

.( ) ¯

. . .

)

. ( ¯ ¯

¯ . . ¯

¯ ¯ ¯ . . .

¯ . . ¯ ¯ ¯ .( ¯

¯ .

)

. :

. ¯ .(

) ¯

−

196

A65/24

Annex

−

. ( ¯ " ¯ ) . . . . " ¯ " "

−

. ( . .

¯ )

−

)

( .(

)

. ) .( .

: ¯

.( )

197

A65/24

Annex

.¯ •

¯ . . . ¯ ¯ . . ¯

•

"¯ " . ¯ ¯

•

.( ) .

¯ ¯ .

¯ .

.( ) : ¯

¯ .(

) ¯

198

A65/24

Annex

) .

¯ . ( : . ¯

•

¯ . . ¯ ¯

•

¯ . ¯ ¯ ¯ ¯ ¯ . ( .¯ . )

.( )

¯ .

(

)

: ¯ −

(

) ¯

− − −

. . . ¯

199

A65/24

Annex

. /

¯ ¯ ) .

)

.( ) ¯

( ¯

)

¯ ... ¯

: "

( ) ." . .

(

) .

200

A65/24

Annex

. .

¯ ¯ . . ¯ /

¯ . . . .

. .

Financing the accelerated development of vaccines for AIDS, TB, and malaria: design of the PDP financing facility and an analysis of its feasibility. A report to Aeras, IAVI, and MVI. Results for Development, Washington 2009 (http://healthresearchpolicy.org/sites/healthresearchpolicy.org/files/PDPFF%20financing%20va ccines%20for%20AIDS,%20TB,%20and%20malaria.pdf, accessed 5 March 2011). The new landscape of neglected disease drug development. London, London School of Economics and Political Science and the Wellcome Trust, 2005 (http://www.policycures.org/downloads/The_new_landscape_of_neglected_disease_drug_devel opment.pdf, accessed 17 October 2011).

201

A65/24

Annex

EWG submission. The Fund for R&D in Neglected Diseases (FRIND). Submitted by Novartis, 2009 (http://www.who.int/phi/Novartis.pdf, accessed 17 October 2011). CEWG submission. Fund for Research and Development in Neglected Diseases. Submitted by Novartis, 2011, (http://www.who.int/phi/news/phi_20_cewg_frind_en.pdf, accessed 17 October 2011). CEWG submission. A global framework on health research and development. Submitted by All India Drug Action Network, Berne Declaration, CENTAD, Initiative for Health and Equity in Society, People’s Health Movement, Third World Network, 2011 (http://www.who.int/phi/news/phi_19_submission_cewg_en.pdf, accessed 17 October 2011). CEWG submission. Maito MA, Franciosi E. A new incentive system for technological innovation in developing countries. 2011 (http://www.who.int/phi/news/cewg_2011/en/index.html, accessed 17 October 2011). Grace C et al. Pooled funds: accessing new models for financing global health R&D. Results for Development Institute, 2011 (http://healthresearchpolicy.org/sites/healthresearchpolicy.org/files/assessments/files/Pooled%2 0Funding%20Technical%20Background%20Paper.pdf, accessed 17 October 2011). The need for global health R&D and product development partnerships message manual. Burness Communications, Washington. November 2011. Moran M et al. G-Finder report 2011. Neglected disease research and development: is innovation under threat? London, Policy Cures, 2011 (http://www.policycures.org/downloads/gfinder_2011.pdf, accessed 12 December 2011). IFFIm web site (http://www.iffim.org/index.aspx).

10.

¯ . .

BUKO Pharma-Kampagne, Charité Universitätsmedizin Berlin, Universität .med4all

Oldenburg.

202

A65/24

Annex

. ¯ .

. .

. . . . " ¯ . " " " "

.( ) "

.( ) . . . . . . " . "

. " . ٕ ( ) " " "

( )

)

203

A65/24

Annex

) .

. .

)(

.( ) ¯ ."Synaptic Leap" .

" (

.( )

)

. .

Sage "

.( ) ( .( " . . " ¯ ¯ ( . . ¯ )

) "Bionetworks " "

" ) . ¯

PLoS ONE

.PLoS ONE . " . " ¯ ( .

. Nature

.(PLoS) .(

)

. 204

A65/24

Annex

( ) . ¯

" .

( ) ( ) . .

¯ •

. ٕ

•

. . •

.( ) Arch2POCM

. ٕ

Sage Bionetworks

. (Arch2POCM) . Archipelago to Proof of Clinical Mechanism

205

A65/24

Annex

( ) ". ¯ .

. .

)

¯ ,

.( )

.( ) . .

)

206

A65/24

Annex

. .

¯ .

¯ ¯

.http://essentialmedicine.org/archive/global-access-licensing-framework-galf-v20 :

. ¯

/ ¯ ¯ ¯ .

. ¯

.( )

" . . ٕ

. ¯ "

207

A65/24

Annex

. . .

Arch2POCM

. . " "

. .

¯ ¯ /

¯ . .

PLoS ONE

. ٕ

¯ ¯ . . . /

208

A65/24

Annex

¯ .( ¯ ) .

. . ¯

1. 2.

Open Innovation web site (http://www.openinnovation.net/about-2/open-innovation-definition). Chesborough H. Pharmaceutical innovation hits the wall: how open innovation can help. Forbes, 25 April 2011 (http://www.forbes.com/sites/henrychesbrough/2011/04/25/pharmaceutical-innovation-hits-thewall-how-open-innovation-can-help, accessed 1 March 2012). Masum H, Harris R. Open source for neglected disease – magic bullet or mirage? Washington, DC, Results for Development Institute, 2011 (http://healthresearchpolicy.org/assessments/opensource-neglected-diseases-magic-bullet-or-mirage, accessed 16 October 2011). Maurer S. Open source drug discovery: finding a niche (or maybe several). UMKC Law Review, 76: 405–435 2007. (http://gspp.berkeley.edu/iths/Maurer_OSBiology.pdf, accessed 16 October 2011). Munos B. Can open-source R&D reinvigorate drug research? Nature Reviews Drug Discovery 5, 723-729 2006 Open Source Drug Discovery Initiative web site. New Delhi, Council of Scientific and Industrial Research, 2011 (http://www.osdd.net/, accessed 16 October 2011). EWG submission. “Open source drug discovery”: an open collaborative drug discovery model for tuberculosis. Submitted by Council of Scientific and Industrial Research, India, 2009 (http://www.who.int/phi/public_hearings/second/contributions/ZakirThomasCouncilofScientific IndustrialResearch.pdf, accessed 16 October 2011). Open Source Drug Discovery Initiative. New Delhi, Council of Scientific and Industrial Research (http://www.who.int/phi/news/cewg_submission_csir_ind.pdf, accessed 1 March 2012).

5. 6. 7.

209

A65/24

Annex

9. 10. 11.

A summary of what is needed right now. San Ramon, CA, The Synaptic Leap, 2010 (http://www.thesynapticleap.org/node/286, accessed 16 October 2011). Sage Bionetworks web site (http://sagebase.org/, accessed 16 October 2011). Davis P. PLoS ONE’s 2010 Impact Factor (blog post, the Scholarly Kitchen blog, 28 June 2011) (http://scholarlykitchen.sspnet.org/2011/06/28/plos-ones-2010-impact-factor, accessed 12 October 2011). Human Genome Project web site (http://www.ornl.gov/sci/techresources/Human_Genome/ project/about.shtml, accessed 16 October 2011). SNP consortium and international HapMap project. London, Wellcome Tust, 2011 (http://www.wellcome.ac.uk/Funding/Biomedical-science/Funded-projects/Majorinitiatives/SNP-Consortium-and-International-HapMap/index.htm, accessed 16 October 2011). Structural Genomics Consortium web site (http://www.thesgc.org/index.php, accessed 16 October 2011). Research and development: coordination and financing. Report of the World Health Organization Expert Working Group on Research and Development Financing. Geneva, World Health Organization, 2010 (http://www.who.int/phi/documents/ewg_report/en/index.html, accessed 16 October 2011). Cain C. Making the case for precompetitive clinical development. SciBX: Science–Business eXchange, 2011, 4:20:7−8 (http://sagebase.org/info/NewsInfoDownloads/Arch2POCM051911scibx.pdf, accessed 16 October 2011). Norman TC et al. Leveraging crowdsourcing to facilitate the discovery of new medicine. Science Translational Medicine, 3, 88mr1, 2011. Friend S. Arch2POCM: a drug development approach from disease targets to their clinical validation (PowerPoint presentation). Sage Bionetworks, 2011 (http://sagebase.org/info/NewsInfoDownloads/IBCFriendAug3.pdf, accessed 16 October 2011). Moran M et al. G-Finder report 2011. Neglected disease research and development: is innovation under threat? London, Policy Cures, 2011 (http://www.policycures.org/ downloads/g-finder_2011.pdf, accessed 12 December 2011). Stevens A et al. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine, 2011, 364(6):535−541, (http://www.nejm.org/doi/ pdf/10.1056/NEJMsa1008268, accessed 12 October 2011). Successes. Oakland, CA, Universities Allied for Essential Medicines, (http://essentialmedicine.org/our-work/successes, accessed 12 October 2011). 2010

12. 13.

14. 15.

16.

17. 18.

19.

20.

21. 18.

Friend S. Arch2POCM: a drug development approach from disease targets to their clinical validation (PowerPoint presentation). Sage Bionetworks, 2011 (http://sagebase.org/info/NewsInfoDownloads/IBCFriendAug3.pdf, accessed 16 October 2011). Moran M et al. G-Finder report 2011. Neglected disease research and development: is innovation under threat? London, Policy Cures, 2011 (http://www.policycures.org/ downloads/g-finder_2011.pdf, accessed 12 December 2011). Stevens A et al. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine, 2011, 364(6):535−541, (http://www.nejm.org/doi/ pdf/10.1056/NEJMsa1008268, accessed 12 October 2011). Successes. Oakland, CA, Universities Allied for Essential Medicines, (http://essentialmedicine.org/our-work/successes, accessed 12 October 2011). 2010

19.

20.

21.

210

A65/24

Annex

) . ¯

( ) ¯ ¯

(( :

¯ )

¯ " ."

" .

¯ ٕ

¯ ¯ ¯ ( .

. . :

¯ ¯

. .

) : ¯ ¯

/ . . .

. ¯ ¯ : :

. . . ¯ ¯ .

. : ¯ ¯ .

211

A65/24

Annex

. / : ) / / ¯ . . ¯ . (" " " " ) . . . . : ¯ ¯ . " . (" ¯ ¯ ¯ " ) . ¯ ¯ . ( . −

−

( ) ." . " . " ¯ . . . ¯

212

A65/24

Annex

(

)

.( )

.( ) . . ( .( ) ¯ " ¯ )

.( ) "

The global health innovation quotient prize: a milestone-based prize to stimulate

.( )

R&D for point-of-care fever diagnostics

( ) Innovation inducement prizes

−

)

. ¯ ٕ " ¯ " .( ) ¯

¯ .

¯ . " . . ¯ ¯

213

A65/24

Annex

. .

¯ . " " .

" "

•

. •

¯ . ¯ •

– BIO Ventures for Global

•

. . Health

¯ .( )

•

214

A65/24

Annex

: X-Prize

. . ¯ . X-Prize

•

. ¯ ¯

•

.( )

¯ . . . . ,

.¯

Innocentive

BIO Ventures for

. ¯ Global Health

¯ ¯

ٕ .

215

A65/24

Annex

. . . . .

¯ ¯ . . . . ¯ – . . . . . /

The Medical Innovation Prize Fund: a new paradigm for supporting sustainable innovation and access to new drugs: de-linking markets for products from markets for innovation. Knowledge Ecology International, Washington 2011 (http://keionline.org/sites/default/files/ big_prize_fund_overview_26may2011_letter.pdf, accessed 16 October 2011). The prize fund for HIV/AIDS: a new paradigm for supporting sustainable innovation and access to new drugs for AIDS: de-linking markets for products from markets for innovation. Knowledge Ecology International, 2011 (http://keionline.org/sites/default/files/ HIV_AIDS_prize_fund_overview_26may2011_a4.pdf,accessed 16 October 2011).

216

A65/24

Annex

3. 4. 5.

X Prize Foundation web site (http://www.xprize.org, accessed 16 October 2011). InnoCentive web site (http://www.innocentive.com, accessed 16 October 2011). And the winner is capturing the promise of philanthropic prizes. McKinsey and Company, 2009 (http://www.mckinsey.com/app_media/reports/sso/and_the_winner_is.pdf, accessed 16 October 2011). Wilson P, Palriwala A. Prizes for global health technologies. Washington, DC, Results for Development Institute, 2011 (http://www.resultsfordevelopment.org/sites/ resultsfordevelopment.org/files/R4D-PrizesReport.pdf, accessed 16 October 2011). CEWG submission. The global health innovation quotient prize: a milestone-based prize to stimulate R&D for point-of-care fever diagnostics. Submitted by BIO Ventures for Global Health, 2011 (http://www.who.int/phi/news/cewg_2011/en/index.html, accessed 16 October 2011). CEWG submission. Innovation inducement prizes. Submitted by Knowledge Ecology International, 2011 (http://www.who.int/phi/news/cewg_2011/en/index.html, accessed 16 October 2011). EWG submission. Chagas disease prize fund for the development of new treatments, diagnostics and vaccines. Submitted by Bangladesh, Barbados, Bolivia and Suriname, 2009 (http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_ChagasPrize.pdf, accessed 16 October 2011). EWG submission. Prize fund for development of low-cost rapid diagnostic test for tuberculosis. Submitted by Bangladesh, Barbados, Bolivia and Suriname, 2009 (http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_TBPrize.pdf, accessed 16 October 2011). EWG submission. A prize fund to support innovation and access for donor supported markets linking rewards for innovation to the competitive supply of products for HIV-AIDS, TB, malaria and other diseases for humanitarian uses. Submitted by Bangladesh, Barbados, Bolivia and Suriname, 2009 (http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_DonorPrize.pdf, accessed 16 October 2011). EWG submission: Prizes as a reward mechanism for new cancer treatments and vaccines in developing countries. Submitted by Bangladesh, Bolivia and Suriname, 2009 (http://www.who.int/phi/Bangladesh_Bolivia_Suriname_CancerPrize.pdf, accessed 16 October 2011). IGWG submission. Priority medicines and vaccines prize fund. Submitted by Barbados and Bolivia, 2008 (http://www.keionline.org/misc-docs/b_b_igwg/prop3_pmv_pf.pdf, accessed 16 October 2011). EWG submission. Response to the Expert Working Group on Alternative Financing. Submitted by Health Action International, 2009 (http://www.who.int/phi/HAI.pdf, accessed 16 October 2011). EWG submission. Comments of Knowledge Ecology International (KEI) to the WHO public hearing for proposals for new and innovative sources of funding to stimulate R&D. Submitted

10.

11.

12.

13.

14.

15.

217

A65/24

Annex

by Knowledge Ecology International, 2009 (http://www.who.int/phi/KEI.pdf, accessed 16 October 2011). 16. EWG submission. Submission to the EWG. Submitted by Medecins Sans Frontières Campaign for Access to Essential Medicines, 2009 (http://www.who.int/phi/MSF.pdf, accessed 16 October 2011). Love J, Hubbard T. The big idea: prizes to stimulate R&D for new medicines. Chicago-Kent Law Review, 2007, 82:3 (http://www.cklawreview.com/wp-content/uploads/vol82no3/Love.pdf, accessed 16 October 2011).

17.

¯ .

( .

. "¯

)

/ ¯

¯ " .

¯ ¯ ,

¯ .( ) ,

.( )

218

A65/24

Annex

.( ) .

.( )

. ¯ ¯ ¯ ¯ . ¯ .( ) ¯ .

¯ . .

¯ ¯ ¯

¯ "

. ¯ ¯

.( ) ¯ ¯ . ¯ ( ¯ ¯ ¯

¯ , .( )

.¯ . )

¯ .( ¯ ¯ ¯ ¯ ¯

)

¯ (

)¯

219

A65/24

Annex

. ,

¯ ¯ ) .( , ) ¯ .( ) . .

, ¯ ( ¯ ,

. . ¯ ¯ . . / ¯

. .

– ¯ ¯ . – ¯ ¯ . ¯ . .

220

A65/24

Annex

About the Pneumoccocal AMC, 2011 (http://www.gavialliance.org/funding/pneumococcalamc/about, accessed 5 March 2011). Jack A. GSK in deal with Brazil for pneumococcal vaccine. Financial Times, 27 September 2009 (http://www.ft.com/cms/s/0/d2890e76-ab93-11de-9be4-00144feabdc0.html, accessed 15 October 2011). Light DW. Saving the pneumococcal AMC and GAVI. Human Vaccines, 2011, 7:138–141 (http://www.es.landesbioscience.com/journals/vaccines/article/14919, accessed 15 October 2011). Baseline study for pneumococcal vaccine AMC. Geneva, GAVI Alliance, 2008 (http://www.gavialliance.org/results/evaluations/baseline-study-for-amc/, accessed 15 October 2011). Levine R, Kremer M, Albright A. Making markets for vaccines: ideas to action. Washington, DC, Center for Global Development and London, Grundy & Northedge, 2005 (http://www.cgdev.org/doc/books/vaccine/MakingMarkets-complete.pdf, accessed 15 October 2011). Light DW. GAVI’s advance market commitment. Lancet, 2010, 375:638 (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60267-X/fulltext#bib1, accessed 15 October 2011). Berman D, Malpani R. High time for GAVI to push for lower prices. Human Vaccines. 2011, 7(3):290−290 (http://www.landesbioscience.com/journals/vaccines/Policy-Berman-HV7-3.pdf, accessed 15 October 2011). Hargreaves J et al. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. Lancet, Early Online Publication, 2011 (http://www.thelancet.com/journals/lancet/article/PIIS01406736(11)60687-9/abstract, accessed 15 October 2011).

221

A65/24

Annex

¯ .

¯ " ¯ " ¯ )

¯ . .

) .( .( ) ¯

(

)

. .( / .

) – . , .

Coartem

. / .( ) .

222

A65/24

Annex

. . . , ) .¯ ( . . . . Coartem

. ( ¯ ) . ¯ .( ) ¯ ¯

.( )

223

A65/24

Annex

¯ .(

)

. ( )" "

ٕ ."

. .( )

. .( ) ¯ .

) .( )

(

. 224

A65/24

Annex

. . . ¯ ¯ . . . . . . . . . .

Department of Health and Human Services. Guidance for industry: tropical disease priority review vouchers. Silver Spring, MD, Food and Drug Administration, 2008 (http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0530-gdl.pdf, accessed 28 July 2011). Ridley D, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs, 2006, 25(Suppl2):313−324 (http://content.healthaffairs.org/content/25/2/313.full.pdf+html, accessed 28 July 2011). Ridley D, Grabowski HG, Moe JL. Priority review vouchers to encourage innovation for neglected diseases. Durham, NC, Duke University, 2008 (http://www.law.harvard.edu/programs/petrieflom/workshops_conferences/2008_workshops/Grabowski.pdf, accessed 28 July 2011).

225

A65/24

Annex

Joseph D. Novartis plays its PRV card. San Francisco, CA, BIO Ventures for Global Health (blog post, 8 July 2011) (http://www.bvgh.org/News/Blog/PostID/71.aspx, accessed 28 July, 2011). Noor W. Placing value on FDA’s priority review vouchers. IN VIVO, 2009, 27(8) (http://www.imshealth.com/imshealth/Global/Content/Document/Placing_Value_on_FDA_Prio rities.pdf, accessed 28 July 2011). Kesselheim AS. Drug development for neglected diseases — the trouble with FDA review vouchers. New England Journal of Medicine, 2008, 359:1981−1983 (http://www.nejm.org/doi/full/10.1056/NEJMp0806684, accessed 28 July 2011). Pope L. E-DRUG: the US FDA priority review voucher and neglected diseases, Geneva, Médecins Sans Frontières, 2008 (http://www.essentialdrugs.org/edrug/ archive/200812/msg00039.php, accessed 28 July 2011).

8. Ridley DB, Sánchez AC. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet, 2010, 376(9744):922–927 (http://faculty.fuqua.duke.edu/~dbr1/research/eu-prv-pre.pdf (preprint), accessed 28 July 2011) 9. Kotiya R. Priority review vouchers: an incremental step forward. Atlanta, GA, Emory Law School’s

Global Health Law & Policy Project, 2009 (http://www.law.emory.edu/fileadmin/ GHLPP/Web_Archives/Rishi_Kotiya.pdf

. .( ) .

226

A65/24

Annex

¯ ¯

. . . . ¯ ¯

¯ .

. ¯ ¯ .

.( ) . ¯

ٕ ¯ ¯ .( ) .

. ¯ . . ¯

¯ .( )

. .( )

227

A65/24

Annex

" " " ¯

.( ) ."

. )

)

(

.(¯

. . . . . .

. . .

. .

228

A65/24

Annex

¯ ¯ . . . . . . . . /

1. EWG report. Report of the World Health Organization Expert Working Group on Research and Development Financing, Geneva, World Health Organization, 2010 (pp.69−71) (http://www.who.int/phi/documents/ewg_report/en/index.html, accessed 14 October 2011). WHO Prequalification web site (http://www.who.int/topics/prequalification, accessed 14 October 2011). The African Medicines Regulatory Harmonisation (AMRH) Initiative (PowerPoint poresentation), 2011 (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/PL2_3.pdf, accessed 14 October 2011). International Conference on Harmonisation web site (http://www.ich.org, accessed 14 October 2011). European Medicines Agency web site (http://www.ema.europa.eu, accessed 14 October 2011). Public health, innovation and intellectual property rights. Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva, World Health Organization, 2006 (http://www.who.int/intellectualproperty/report/en/index.html, accessed 14 October 2011).

5. 6.

229

A65/24

Annex

Moran M et al. Registering new drugs: the African context. Sydney, The George Institute for International Health, and Geneva, Drugs for Neglected Diseases initiative, 2010 (http://www.policycures.org/downloads/DNDi_Registering_New_DrugsThe_African_Context_20100108.pdf, accessed 14 October 2011).

.( ) . .

(

¯ )

230

A65/24

Annex

¯ . .

. .( ) . ¯ ¯ .( ) .( ) .( . ) . . .( ) ( . )

) (

.( ) .

. . . 231

.( )

¯ ¯

A65/24

Annex

¯ ¯ . . . . . . . . . /

1. Vaccines research relief: introduction of a new scheme and modification of state aid. Brussels, European Commission, 2003 (Document N 802/99 C(2003) 1398) (http://ec.europa.eu/eu_law/state_aids/comp-2002/n228-02.pdf, accessed 15 July 2011). Rao A. Can a R&D tax credit expand investment in product development for global health? Results for Development Institute Center for Global Health R&D Policy Assessment, 2011 (http://healthresearchpolicy.org/sites/healthresearchpolicy.org/files/assessments/files/Tax%20Cr edit%20Draft%20Consultation%20Draft%202%2028.pdf, accessed 15 July 2011). Rao A. R&D tax credits: a tool to advance global health technologies? Results for Development Institute Center for Global Health R&D Policy Assessment, 2011 (http://healthresearchpolicy.org/assessments/rd-tax-credits-tool-advance-global-healthtechnologies, accessed 15 July 2011). Corporate tax: research and development tax credits. London, HM Revenue and Customs, 2009 (http://www.hmrc.gov.uk/stats/corporate_tax/randdtcmenu.htm, accessed 15 July 2011).

232

A65/24

Annex

Qualifying therapeutic discovery project credits and grants. United States Department of the Treasury Internal Revenue Service, 2010 (http://www.irs.gov/businesses/small/article/ 0,,id=228690,00.html, accessed 15 July 2011). Moran M et al. G-Finder report 2011: neglected disease research and development: is innovation under threat? London, Policy Cures, 2011 (http://www.policycures.org/downloads/g-finder_2011.pdf, accessed 12 December 2011).

¯ ¯ ¯ :

¯ . . .

−

. ¯

− −

233

A65/24

Annex

¯ ¯ .

. ¯

.¯

. . ¯ ¯ .¯

. ¯

. .

( )

. ¯ ¯ . .

234

A65/24

Annex

¯ − −

. .

−

¯ ¯ . . . . . . . ¯

235

A65/24

Annex

Towse A. A review of IP and non-IP incentives for R&D for diseases of poverty. What type of innovation is required and how can we incentivise the private sector to deliver it? Final report for the WHO Commission on Intellectual Property Rights, Innovation and Public Health. London, Office of Health Economics, 2005 (http://www.who.int/intellectualproperty/studies/A.Towse.pdf, accessed 28 July 2011).

236

A65/24

Annex

. . ¯

. . . / . . . . . : . ¯ / ¯ / /

http://www.who.int/phi/news/cewg_regional_consultations/en/index.html

237

‫ج‪ ٢٤/٦٥‬ﺗﺻوﻳب ‪١‬‬ ‫ﻣﺎﻳو ‪٢٠١٢‬‬ ‫‪ ١١‬أﻳﺎر‪ /‬ﻣ‬ ‫‪A65/24 Corr.1‬‬

‫ﻟﺳﺗون‬ ‫ﻟﺧﺎﻣﺳﺔ واﻟ‬ ‫ﺟﻣﻌﻳﺔ اﻟﺻﺣﺔ اﻟﻌﺎﻟﻣﻳﺔ اﻟ‬ ‫ﺔ‬ ‫ﻣﺎﻝ اﻟﻣؤﻗت‬ ‫‪ ١٤-١٣‬ﻣن ﺟدوﻝ اﻷﻋﻣ‬ ‫اﻟﺑﻧد ‪٣‬‬

‫ﺗﺷﺎرﻳﻳن اﻟﻌﺎﻣﻝ‬ ‫ﻝ‬ ‫ن‬ ‫اء اﻻﺳﺗ‬ ‫ﻓرﻳق اﻟﺧﺑرء‬ ‫ق‬ ‫وﻳر‬ ‫اﻟﺑﺣث واﻟﺗطو‬ ‫ث‬ ‫ق‬ ‫ااﻟﻣﻌﻧﻲ ﺑﺗﻣوﻳﻝ وﺗﻧﺳﻳق‬ ‫ب‬ ‫ﺗـﺻـوﻳــب‬ ‫ﻛﻣﺎ ﻳﻠﻲ‪:‬‬ ‫اﻟرﺟﺎء ﺗﻌدﻳﻝ ﻋﻧوان اﻟﺟدوﻝ ‪ ١-٤‬ﻣن اﻟﻣﻠﺣق ﻛ‬

‫ﻋﻠـﻰ اﻟﺻـﺣﺔ‬ ‫ﺣﺔ‪ ،‬واﻹﻧﻔـﺎق اﻟﺣﻛـوﻣﻲ ﻋ‬ ‫ﻣﺟـﺎﻝ اﻟﺻـﺣ‬ ‫ﻟﺗطـوﻳر ﻓـﻲ ﻣ‬ ‫ر‪ ،‬واﻟﺑﺣث واﻟ‬ ‫ﺣث واﻟﺗطوﻳر‬ ‫اﻟﺟدوﻝ ‪ :١-٤‬اﻟﺑﺣ‬ ‫ﻝ‬ ‫ن‬ ‫ﺔ ﻓـﻲ‬ ‫ﻓﻲ ﻋﺎم ‪ (٪ ) ٢٠٠٩‬ﻓﻲ ﺑﻠدان ﻣﻧظﻣﺔ اﻟﺗﻌﺎون واﻟﺗﻧﻣﻳـﺔ‬ ‫ﺑﻧـﺎء‬ ‫اﻟﻣﻳـدان اﻻﻗﺗﺻـﺎدي وﻓـﻲ ﺑﻠـدان أﺧـر‬ ‫ى ً‬ ‫ﺻﺎدي‬ ‫ﻣﻳدان اﻻﻗﺗﺻ‬ ‫ﻟﺗﻧﻣﻳﺔ ﻓﻲ اﻟﻣ‬ ‫ﺔ اﻟﺗﻌﺎون واﻟ‬ ‫ﺑﻳﺎﻧﺎت ﻣﻧظﻣﺔ‬ ‫ﻋﻠﻰ ﺑﻳ‬

‫=‬

Основные сведения

Организация Всемирная организация здравоохранения (ВОЗ / WHO)

Тип документа Governing Bodies documents

Дата принятия 31 декабря 2012 г.

Источник Всемирная организация здравоохранения